b e h r n g e r n g e l h e agility value innovationc n e n enquire agility mean c u r g e right thing strategic decision demand great flexibility courage involve discussion integration new animal health take courage new road objective effect new people strategy focus art see clearly good world boehringer ingelheim new animal health overview n e e f r h e b g product brand prospect p c u r e little thing dr michael mark team research anna vgh tell life rare autoimmune ing active ingredient treatment disease scleroderma cardio metabolic disease c r e v transformation meet tradition visit bi x boehringer ingelheim new digital lab digitise swing worldwide boehringer ingelheim sought find consistent imaginative answer change image gallery f r e g h eye big picture boehringer ingelheim scientific department estab lishe year ago oday spirit research live innovation unit focus patient interview dr oliver reu approach actual medication turn point guest contribution explain china important location research drive pharmaceutical h e b e f b h company world w r l imprint integration new animal health swing course set growthe x p l r e h e n e r c v e c n e n annual report smart symbol magazine start video straight correspond e smartphone tablet e p download layar app smart phone tablet open app e p hold device like watch additional video content tap screen scan device scan video open directly play e p wish view video screen tap video play e p press close symbol exit video n e n c r n f r n e e r n goal new digital lab bi x create innovative digital solution researchdriven pharmaceutical company h ttpsplaygooglecomstore h ttpswwwapplecomio appstore h e l l e h n g horse help scleroderma patient anna vgh cope diseasee x p l r e h e n e r c v e c n e n annual report smart symbol magazine start video straight correspond e smartphone tablet e p download layar app smart phone tablet open app e p hold device like watch additional video content tap screen scan device scan video open directly play e p wish view video screen tap video play e p press close symbol exit video n e n c boehringer ingelheim glantcr aen f r n e e r n goal new digital lab bi x boehringer ingelheim world lead create innovative digital solution pharmaceutical coremseaprcahndireivsen pharmaceutical company eur billion found total net sale ingelheim eur familyowne day httpsplaygooglecomstore httpswwwapplecomio appstore billion expenditure research development employee worldwide total net sale e u r e u r e u r b l l n b l l n l l n h e l l e h n g horse help scleroderma patient anna vgh cope disease human pharmaceutical animal health biopharmaceuticalsour company improve health quality life patient goal researchdriven pharmaceutical company boehringer ingelheim focus disease satisfactory treatment option exist date company concentrates develop ing innovative therapy extend patient live animal health boehringer ingelheim stand advanced prevention familyowne establish boehringer ingelheim pharmaceutical industry company employee create value innovation daily business area human pharmaceutical animal health biopharma ceutical boehringer ingelheim achieve net sale billion euro rd expenditure exceed billion euro correspond cent net sale familyowne company boehringer ingelheim plan generation focus longterm success shortterm profit company aim organic growth resource simultaneous openness partnership strategic alliance research boehringer ingelheim naturally adopt responsibility mankind environment l g kreativitt w h g l e n f r u role agility play boehringer ingelheim tradition boehringer ingelheim initial success familyowne company base industrial production acid massproduced chemical raw material patentprotecte pharmaceutical specialty require build successful research operation call understand new customer class physician example agility turn lead research drive pharmaceutical company today serve inspiration current transformation healthcare market adapt need finance healthcare system christian boehringer chairman shareholders committee l g ahow influence agility integration new animal health business animal health agile company currently engage building boehringer ingelheim new unit bring successful company give opportunity regroup truly core business cornerstone common culture agility agility embed agile allow boehringer ingelheim process flexibility adapta bility increase contribution patient call order meet require company health offer new ment customer position innovative therapeutic option expand lead position breakthrough answer medical highly competitive market successfully need human market animal new technology collaborate partner intensely network dr joachim hasenmaier able manage large datum member board manage director successful market enable target medicine responsibility animal health crucial company b usiness unit precisely individual patient agile agility require make product area excellent customer effective increase benefit understand agility react society change customer perception expectation agility react change market condition hubertus von baumbach finally agility respond competi chairman board manage director tor action strategy important increase competitiveness allan hillgrove member board manage director responsibility human pharma business unit u r f n e l ga hwhow agile boehringer ingelheim employee secure company future change new normal change change agility journey start end drive company unclear agility agility organisation employee come financial success mean b oehringer play agility opposite structure fact require ingelheim innova discipline approach decision tive capability agility pre condition make combined accountability economic success intrapreneurship powerful reason want recognise recipe success fast change internal agility require day external condition early journey idea draw right conclusion dr andreas neumann innovation indispensable matter act rapidly member board manage director timely integration new information necessary diligence responsibility human resource allow learn failure overcome future challenge compete build small win step step successfully deliver well achieve breakthroughs service customer dr michel pairet michael schmelmer member board manage director member board manage director responsibility innovation unit responsibility finance l g acourage g l n e e c u r g e right thing strategic decision demand great flexibility courage people involve animal health organisation boehringer ingelheim sanofi merge corporate culture different nationality find way single melting pot boehringer ingelheim new animal health business unit rogier bieman site director pirbright uk originally boehringer ingelheim organisation vanessa mariani global commercial operation integration lead merial employee discuss bring good world l g arogier transfer rule dress code stricter vanessa mariani boehringer ingelheim site weesp conversation formal rogier bieman meet october netherlands pirbright uk know people loosen ingelheim work vanessa leave atlanta usa boehringer ingelheim come ingelheim mariani notice certain formality new animal health courage ingelheim like business unit appreciate framework rule bieman not easy tell live different day say goodbye colleague flexible despite hard like formality ve create space try stay lot relaxed touch life move interact people uk treat approach different situation vanessa spend mariani game life north america working changer atlanta work merial germany challenge m boehringer ingelheim ve live ingelheim march mariani work global corpo stay march rate world rare find extend business trip not interact husband live atlanta try culture positive fly home week ingelheim culture way ve felt welcome bieman job boehringer ingelheim organisation busy s time miss old integration team ingelheim way general fantastic experience mariani s true change personally people boehringer ingelheim location m touch merial general company colleague work atlanta try integrate business people ingelheim form single entity right vanessa mariani amazing welcome vanessa mariani move ingelheim s d change bieman process ongoing germany spring global commercial operation integration continue lead transfer boehringer vanessa live rural upcoming month difference ingelheim merial area go far corporate structure responsible strategic planning huge merial multinational public marketing excellence originally mexico city mariani live mariani originally mexico company boehringer ingelheim life new york city city live new york city privately hold global organisation move atlanta year ingelheim definitely change ingelheim like not suffer mariani combine cultural shock thing take business develop new vision little bit sunday drive conviction rogier bieman stores close germany animal enrich human life vital rogier bieman currently integration process boehringer ingelheim site director pirbright uk moving size town take common set belief great london area august time people dutchman work produc different s special boehringer ingelheim merial tion manager boehringer boehringer ingelheim headquarters unique corporate ingelheim site weesp netherland bieman year culture corporate culture experience life sciences pharma bieman visit ingelh eim mean ceutical research development feel people correct value manufacture e g r u c e e n l g abiemans people interact relate underlying value boehringer ingelheim structure way work people correct respectful create certain atmosphere determine people interact mariani culture society large corporation behaviour everyday life write code live underlie value build culture main difference culture merial boehringer ingelheim mariani find merial lot lax open structur e daily business probably fact previously joint venture give organisation great freedom operate bieman agree begin year global operation conference merial headquarters lyon threeday conference lunch everybody wait vanessa mariani rogier bieman agenda send arrive exchange view lyon wait agenda boehringer certainly informal ingelheim corpo improvised boehringer ingelheim rate culture people mariani yes people come lax environment tight framework little bit shock ve work loca tion culture differ place bieman boehringer ingelheim s common corporate culture certain element unique location country hugely influence way people interact type location play role production site office l g amariani feel animal health mariani right combine different corporate general people passionate create respect different part culture not easy industry social purpose team boss example teambuilding activity work fulfil dr usually transition easy right thing animal people establish certain distance industry people work hard approachable person mariani deal location country find work team room sanofi boehringer ingelheim s doctor conclude different country day right thing specific engineer architect event integration workshop animal health matter s get commit team ingelheim organ ment respect work ise quarterly social activity like go mariani ve work field title dinner year spective intrinsic bieman feel thing bieman transfer animal health ve find change germany uk onboarde good people time ve ingelheim formal today nice open straight intrinsic overall boehringer forward pirbright get ingelheim culture ask card birthday not selve well approach previous site weesp like new longterm gain fit idea good good overall strategy try world use right thing right reason long term refresh s link stereotype arise today tomorrow work different culture not company bieman british strong bieman agree humour not think s stereo example product type appreciate vigorous uk vaccine footandmouth exchange view rogi bieman move disease fmd sell govern enjoyable little bit boehringer ments department ingelheim site weesp veterinary public health lyon netherlands pirbright uk vaccine change people live mariani ingelheim melt pot vanessa mariani come people product funda different nationality atlanta usa mental fundamental ingelheim not stereotype work realise different people place main difference englishspeake country germa bieman individual different ny people work fact come certain address german use country not pigeonhole name formal word formal informal german retain certain distance heat cool mexican find mariani work people bieman uk hardly use columbia spain spanish people atmosphere speak country joke relaxed animal health little accent colloquial bit casual area ism good humour pharmaceutical industry production location particular formal bieman happily like opinion boundary joke commu establish name nicate level mat ter underlie factor underlie respect e g r u c e e n l g ajoachim larsen role people strategy manager responsible development implementation people strategy work boehringer ingelheim copenhagen office k e c u r g e k e n e w r g e h e r s goal new people change new people important strategy boehringer ingelheim strategy entail management implement worldwide employee larsen take courage beginning new road adapt larsen support individual organisation change environ larsen face challenge department business area subsidi ment employee want know rapidly adapt position arie answer today position role responsi effectively competitive develop necessary competency bilitie company today increasingly volatile market tomorrow challenge basis tomorrow essential environment achieve good understanding hr acknowledge yes ve objective company right strength weakness get agile respond employee right competency describe competency need accordingly end successful right time ve establish prepare employee business allow create new job strategic basis people accordingly special emphasis exist one vice versa strategy aid structure provide appropriate training talente highly motivated people holistic approach aspire identify implementation people strategy help company employee competency sharpen ability handle flourish key future success future challenge l g ao u r f c u h e r f e e n g c l e r l focus framework help concentrate effort need e g r u c e e n l g awho want work achieve goal core leitbild boehringer ingelheim commitment agility independent serve mankind meet quickly act open mind face familyowne company prefer partner admire competi internal external transformation intend remain tor earch respond driver w e drive desire n umber animal health change active experiman serve mankind improve human n umber biopharmaceutical tation animal health contract manufacture c hallenge status quo w e feel responsible commu n umber value share assumption nitie respectful brand human pharma political bias resource q uickly turn data insight w e plan generation focus aspire grow sale insight action longterm performance billion euro l earn open mind rarely mistake twice create value accountability innovation ambiguous circumstance customer demonstrate ownership decision action w e develop breakthrough therapy health care solution area r ole model boehringer ingelheim unmet medical need value focus w e excel innovation deliver say think high quality drive catalyst unlock ake timely decision competitiveness balanced analysis intuition w e believe partner success potential particularly tough situation sustainable economic r uthlessly prioritise drive boehringer health company execution excellence discipline collaboration ingelheim ctively seek feedback power leverage strength people deliver result develop individual w e nurture diverse collaborative open environment intrapreneurship appeal good people customer create w e drive result work innovative idea respond change integrity passion market w e treat respect trust empathy grow erve need customer patient turn innovative idea business result ake smart risk leverage possible opportunity include resource talent emonstrate win spirit create cando attitude positive energy eliver high quality result despite challenge condition l g ause collective power year pass boehringer ingelheim acquire competitor sanofis animal health business merial integration underway set growth boehringer ingelheim intend animal health business market leader e g r u c e e n l g aa gg ii ii tt yy nn ee ee dd ss cc oo uu rr aa gg eeboehringer ingelheim vision boehringer ingelheim researchdriven pharmaceu animal health global market position tical company want create world animal long suffer avoidable disease target prevention work help stop occur place boehringer ingelheim convince create animal healthy human world healthy realise vision boehringer animal ingelheim acquire merial animal health business pharmaceutical long company sanofi january pet equine acquisition bring highly suffer compatible portfolio strengthen avoidable boehringer ingelheim competitiveness field animal health follow disease integration merial net sale swine veterinary animal health double public provide fifth health total group net sale employee business unit worldwide boehringer ingelheim offer animal health product market merial boehringer ingelheim fit like piece jigsaw puzzle combination strength boehringer ingelheim enable boehringer ingelheim avian cattle leader livestock segment merial advantage market potential bring leadership companion animal potential enormous global leader cat dog forecast predict net sale global animal health market double billion euro reflect grow world parasiticide vaccine population world pop ulation reach billion sale split specie current demand meat animal double triple healthy increase globalisation human strong link different country continent mean healthy infectious animal disease frequent livestock future companion trend people animal spend increasingly large sum money pet dog cat domestic animal long member family l g aboehringer ingelheim optimally competition fierce position integrate product animal health market research portfolio feature development key factor future product dog cat horse pig success growth scien cattle poultry follow acquisi tist support staff conduct tion merial boehringer ingelheim research site globally secondbigg player glob order stem spread disease al animal health market goal occur year clear boehringer ingelheim core segment vaccine parasiticide aims market leader product pharmaceutical boehringer animal health today ingelheim intend expand pet dog cat horse pig company leader health care diagnostic live cattle poultry area vaccine parasiticide therapeutic segment able boehringer ingelheim offer customer broad number pet equine swine solution future field veterinary public health aim catch poultry cattle acquisition bring highly compatible portfolio strengthen boehringer ingelheim compe titiveness field animal health e g r u c e e n l g athe new animal health business focus prevention boehringer ingelheim long tradition prevention animal health follow integration merial thank strategic partnership external partner novozyme boehringer ingelheim able offer innovative solution future partnership novozyme boehringer ingelheim novozymes alliance currently test order boost expertise phase set market launch field prevention boehringer boehringer ingelheim leader livestock segment merial ingelheim enter strategic bring leadership companion partnership danish biotech com animal cat dog nexgard combat parasite pany novozyme march year new partner dog flea owner soon face want work develop challenge pest burrow deep live therapeutic product poultry dog fur skin hatchery novozyme like jump surrounding responsible research untreated flea cause health development work boehringer problem dog human ingelheim market differen tick make preven tiate solution product tion important line floramax probiotic product novozyme portfolio thank integration merial boehringer ingelheim portfolio probiotic increasingly include nexgard family important alternative antibiot medicine nexgard administer ic play beefflavoure chew major role preventive health living launch oral medication microbe positive impact treat flea tick dog intestinal flora balance poultry currently bestselle pet medica animal provide tion animal health industry specific health benefit case certain market boehringer ingelheim produce distinct compound recently launch nexgard spectra help immune system add protection dog mature lead healthy gut certain internal parasite probiotic product datum file l g e g r u c e e n l g courage g l n e e c u r g enothe anna vgh learn suffer scleroderma rare autoimmune disease anna find way happy life despite condition little thing anna sit mother mother awful hospital waiting room disease ask time petite young woman later annas doctor tell auburn hair nervous anxious suffering scleroderma lie ahead year ago experience severe pain rare disease scleroderma know week suffer particularly systemic sclerosis cause swell painful sensation stomach scar connective tissue hand breathing case lung organ bad morning evening gradually suffer scar know cause lifethreatene patient explain annas skin change disease affect million suddenly feel different rough people worldwide mainly woman thick doctor unable account age family frighten world completely fall hungarian woman live small apart anna recall town szombathely simply want doctor assure patient know happen maintain good quality life know sense disease feel seriously ill sit happy simply not hospital waiting imagine lead nice minute slowly pass poster catch life disease like say anna annas eye head scleroderma year old time display fact disease lot research order find image people suffering face find anna shock lean absolutely terrifying find l g apositive example find body suffer disease talk thing completely time note experience symptom mobility decline breath rapidly hobby fall ill go gym time week exercise spin bike come point long manage simply not strength frustrated say anna regularly take medicine attend hospital checkup suddenly extremely restrict entirely normal everyday situation not use credit card strain hand purse horse sense mood feels luckily include ride anna turn special antidote horse like therapy anna anna learn help come time week spend time term disease cope disease notice ride school outside szombathely important thing ride regularly capable say sport engage keep job quality manager horse sense mood important col league continue treat normally today m grateful comfort day not feel able job little thing think good social life change result future day spend sun disease family feel afraid tell ve horse forget important thing mother bad illness place mean absolute brother sister leave happen naturally relaxation bad thing test consultation aware disease day anna longer doctor friend lot dominate life think ride eventuality neverthe strength important know medicine plan continue visit disease not away hospital appointment horse despite lung capacity reason meantime anna cent breathing exercise anna decide public happy maybe hap medicine help thing story order encourage pier diagnosis simply long possible sufferer like clear e g r u c e e n l g amore scleroderma scleroderma systemic sclerosis ssc rare far incurable disease characterise harden skin connective tissue affect million people worldwide time woman man mainly midlife lung disease common manifestation systemic sclerosis particularly patient develop pulmonary fibrosis extent boehringer ingelheim leader respiratory medicine conduct active research potential fatal consequence fibrotic lung disease year global initiative scleroderma inside story boehringer ingelheim pursue goal educate society provide information disease interested end company collect inspiring story patient world publish brief portrait live website wwwboehringeringelheimcom portrait video interview photo series sufferer read anna long look stud farm keep horse paddock patient cope like huge space disease time learn horse enjoy give sense clear freedom ride progression disease paddock effect initiative seek scare people contrary goal patient disease determine life find way cope portrait forget poster patient seven country wait room see horror currently feature website scenario make bad instead hear people live happy life spite university michigan scleroderma program wwwmedumichedusclerodermapatient disease people like anna sclerodermahtm l g acreativity g l n e e c r e v transformation meet tradition wild sketch brightly paint office wall furcovere stool bi x boehringer ingelheim new digital lab look like work space startup san francisco berlin goal innovative digital solution researchdriven pharmaceutical company bi x mark begin transformation company digitisation boehringer ingelheim swing l g aeven project fail indirectly lead success later learn look new bi x company found summer digital lab boehringer comparably small ingelheim campus ingelheim staff new face germany stand good chance join team month mid get lose minute walk talented tech specialist main gate building locate work digital lab edge little wood company seek experienced expert unassume oldfashione bring indepth know outside inside ledge industry methodical look like startup digitisation pioneer desk people work necessary passion implement suit time foyer initiative visions conviction lounge corner large wooden formally bi x subsidiary table kitchen boehringer ingelheim digital lab spontaneous idea instantly jot de facto startup synergies marker pen writable parent company create benefit wall large window everyday work easy view greenery bright postit independent company bi x benefit note stick idea greatly freedom startup lose technology impressive triedandteste room process globally lead pharma giant touchscreen addition ceutical company example unconventional tool small come contract approval process building block case quick tangible es say schmelmer give model call people time bi x new world meant specifically boehringer ingelheim way work distinguish ingelheim site people predominantly bi x clearly rest dress traditional businesswear lab coat company tech expert work overall dr daniel hach open accordance late agile door bi x trainers tshirt planning method yearold people fact employ digital lab respon lead instant success sible fourman management plan failure allow bi x states team daytoday operation schmelmer bi x consciously visit october meet michael work highrisk project hard schmelmer head bi x implement average half boehringer ingelheim chief project successful setback information officer cio learn process v e r c e e n l gawante innovation bi x project bi x development cycle michael schmelmer explain phase idea closely align business parent company example bi x team develop software researcher easy list good idea analyse datum late scientific insight long world identify possible window bi x turn relationship example certain protein pinboard concentration recognise possible therapeutic approach medication development speed team currently second wave generate idea develop new appro ache connect boehringer ingelheim business disruptive capable open new business area bi x team instance develop app digital early detecti alzheimer disease aim determine analyse speech person show early sign disease alzheimer research link traditional business boehringer ingelheim app offer service exist form s like michael schmelmer bi x aim lead boehringer ingelheim future say wave team want new digital movement team assignment work innovative solution enterprise potential shake market schmelmer put come time bi x mature start topic gauge process place team know bi x works address highrisk matter kind schmelmer wants reveal cfo boehringer ingelheim january l g asuccessful implementation thing count project fail indirectly lead success later learn learn mistake bi xs dna mission statement literally writ large foyer challenge day risk mistake pride play rule bi x manifesto states member staff develop mission statement new approach morning boehringer ingelheim like fact bi x team agree team decide priority want achieve want day work member plan say schmelmer lot boehringer ingelheim large corporation particular need term digital transfor usual staff level mation recall august organisation strategy decision week collect idea quickly easy clear want action schmelmer accept decisionmak basic e freedom staff bi x bi x independent beginning need term learn process handsoff subsidiary boehringer ingelheim office space technology staff try intervene dayto focus innovative digital company look like day run bi x solutions healthcare sector ingelheim right place digitisation strategic importance quickly clear bi x boehringer ingelheim bi x need near parent company hope offer well startup work closely company headquarters bi x team treatment option patient find suitable building future goal combine boehringer ingelheim business guest restaurant time expertise global research drive human pharmaceutical animal occasionally internal pharmaceutical company techno health biopharmaceutical training session modification take logical knowhow integrate month bi x team move newly acquire knowledge june classic pharma business last bi x develop product team include maria apsolon basis boehringer ingelheim see prototype solution estonia join bi x powerful development potential test pilot phase software specialist october organisation frontend developer digitally customer mind support implement design develop man agement boehringer ingelheim idea currently work company combine aspiration invest platform pharmaceutical possible researcher collect structure million euro say schmelmer exchange datum start bi x birth bi x come spring bi x frontend developer idea structure digital pressure say look initiative boehringer ingelheim work hard lot desire grow rapidly end worth develop product small team digitalthinke col difference people league external strategist opinion make bi x stand form jointly develop bi x special way work concept hach external consult work bi x number set tech expert work flexibly ant board discuss increase mid scrum method start v e r c e e n l gaproject phase generally last need right people bi x spread entrepreneurial spirit week clearly define order successful say schmelmer innovative working technique measurable goal individual project want draw talented staff digital lab entire step flexible location exciting content company thing clear emerge course process work people actually quality associate start apsolon say project staff bring change agile flexible resultdriven divide new team compris working solution work factor success e data scientist scrum master potentially save life future traditional company like frontend backend developer bi x team plan boehringer ingelheim user experience designer limitless current year want daily standup implement project member staff briefly explain possible boehringer ingelheim priority day end help build idea hach project phase team look say initial support result decide impact direction direction project need adjust progress see member staff foyer future bit byte status project display large screen boehringer ingelheim aim fully exhaust digital potential team set goal respec build multiple initiative selection tive week schmelmer say s immense performance culture bi x want difference feel independent subsidiary bi x promote smart healthcare solution counter balance hard business area human pharmaceutical animal health biopharmaceutical work team enjoy regular time order develop digital business idea business area turn bi x out week team go digital lab helps clearly define idea deliver prototype dinner try restaurant area new product failure expressly allow decisive try new go right project technology possibly reach goal indirectly table football foyer come different idea business model healthcare innovation winner decide innovation team locate human pharma business unit work joke apsolon closely expert therapeutic area expert frontend developer recognise need early work jointly partner target solution estonian team colleague come country like usa concentrate intensively digital healthcare solution base modern spain austria netherlands hungary information communication technology interview dr oliver reu bulgaria bi x office language english accident different nationality come work boehringer accelerate ingelheim focus diversity initiative accelerate boehringer ingelheim employ innovative inclusion year company potential employee worldwide submit proposal certain diversity major driver innovation growth digital innovation interdisciplinary jury decide submitter international talent implement proposal desire timeframe international demand undoubtedly mainly month subsequently report experience people head ingelheim project meantime fail important everybody learn preferred job location s text hololens project great challenge face bi x l g ao n h e v e w r l w e past year boehr inger ingelheim dr iven var ious project cover ing var ie topic common openminde employee w ith sense responsibilit consistentl invent ivel seek answer change find v e r c e e n l ga creativityt h e p w e r f n f l u e n c e r social network actively harness power influencer new phenomenon company boehringer ingelheim japan take concept tailor researchdriven pharmaceutical company young employee know change champion start push ahead new global principle work roll agility accountability intrapreneurship aai aai change champion connect informal network work facilitator influencer storyteller frontrunner instruction develop goal initiative seek dialogue colleague practical approach develop favourable dynamic inspire side surprise second generation aai change champion start block l g aa f r k k afrika kommt africa come initiative allow specialist africa exchange view manager major german corporation effect change found member research drive pharmaceutical company boehringer ingelheim support initiative foster diversity pharmacist simon manyara kenya participate programme boehringer ingelheim site ingelheim germany month fellowship simon continue support project corporate strategy development boehringer ingelheim l e r n n g u n e r ta n p e n b e e r important patient unfulfilled need research tangibly apply help address need order question boehringer ingelheim launch scorecard project usa march crossdisciplinary team look far therapeutic area traditional researchdriven pharmaceutical company work close cooperation patient improve clinical trial gain well understand patient need employ questionnaire oneonone patient interview moderated online discussion digital consultation platform v e r c e e n l gav r u l p g pig romp boehringer ingelheim corporate site ingelheim germany animal see people wear special goggle microsoft hololens allow interactive image project immediate environment hand movement herd pig touch hear gentle grunt tool like future help farmer administer medicine animal long way aim boehringer ingelheim fraunhofer institute software system technology isst test threemonth pilot project opportunitie new technology offer employee department request research innovative dynamic digital approach company special accelerate internal platform boehringer ingelheim agree request support development pilot project euros l g g e h e r f e r n g c l n n vat n day october participant variety country gather boehringer ingelheim campus ingelheim germany joint objective drive future success make health mmh initiative found boehringer ingelheim ashoka mmh foster social innovation world explore unconventional partnership business model encourage boehringer ingelheim employee mmh convention give participant opportunity network inform innovative local international mmh project unleash new cooperation pillar provide framework cocreation bond social responsibility business social innovation social entrepreneur mmh network foster entrepreneurial intrapreneurial thinking changemaker programme innovative way develop leadership skill convention deliver exhibition different workshop success story panel discussion interview v e r c e e n l gaa c c e l e r n g h e e v e l p e n f u n n c l g h e r p e combination immunooncology therapy concept essential boehringer ingelheim cancer research strategy focus turn tumour hide immune system visible enable bodys immune system recognize attack tumour approach commonly describe turn cold tumour hot tumour researcher focus novel approa che result breakthrough treatment patient difficulttotreat condition lung cancer g astrointestinal cancer despite recent treatment advance lung cancer number cancer killer gastrointestinal tumour increase importance year frequent cancer asia bring result oncology research patient quickly boehringer ingelheim collaborate sarah cannon cancer research institute conduct clinical trial expertise partner support researchdriven pharmaceutical company identify right patient optimally support clinical trial meaningful result high quality achieve timely manner boehringer ingelheim goal remain accelerate development innovative cancer treatment patient high therapeutic need l g ar g e f e l e b e v e r open unbiased way thinking require correspond work environment boehringer ingelheim reshape ridgefield site usa inclusive campus completely redesign diversity inclusion mind workstation parking place bathroom facility example redesign auditorium wheelchair access technology support employee hear impairment project instigate implement ridgefield workforce clear example change team able bring pull c v e r p f n e n v r n e n difficult correctly interpret symptom rare disease idiopathic pulmonary fibrosis ipf fast diagnosis decisive denmark virtual reality game help doctor hone awareness example interpret lung noise virtual world investigate healthy lung tissue ipf sufferer boehringer ingelheim brand communication team denmark develop game record time year employ time annual conference danish lung specialist v e r c e e n l gat w e lv e c e n w e lv e n h todays modern worker desire flexibility healthy worklife balance innovative company like boehringer ingelheim identify transformation turn programme remote year support inspiration remote year organise development programme bring mix international professional free lancer entrepreneur live work community global city year remote year promise provide personal professional growth give participant opportunity learn immerse different local culture business ecosys tem annemadeleine kleinwchter global senior manager leadership development boehringer ingelheim boehringer ingelheim employee programme annemadeleine itinerary cover emerge mature market consist city eg prague lisbon kyoto kuala lumpur chiang mai buenos air mexico city picture annemadeleine colleague work kyoto japan l g aa b u c n r u c n p r j e c speed game boehringer ingelheim new manufacturing facility respimat pocket inhaler sant cugat spain production september groundbreaking ceremony take place june path point involve hurdle project engineering team ultimately able stay schedule obtain planning permission local authority future boehringer ingelheim manufacture million cartridge respimat inhaler year package finished product sant cugat v e r c e e n l ga l g ai n v e f r r k e p e n begin october dubai united arab emirates stroke center set support boehringer ingelheim meta stroke initiative quickly expand rest meta region consist middle east turkey africa region second count treatment stroke patient live initiative aim create stroke center excellence region spread knowledge experience locally result initiative thrombolysis rate increase cent initiative establish cent initiative focus country board include specialist country boehringer ingelheim health authority objective heighten public awareness stroke initiative succeed increase number treat stroke patient incidence stroke rise world meta stroke initiative boehringer ingelheiminitiate angel initiative cooperate lead stroke organisa tion expert goal improve acute stroke care patient worldwide w h e n w b e c e n e year change boehringer ingelheim animal health business competitor previous stranger colleague supervisor order transition seamless possible staff boehringer ingelheim animal health philippine organise camp project team building activity call mental agility everybody understand merger mean operate outside comfort zone project success new animal health business philippine enjoy significant increase sale second half year v e r c e e n l gas h w n g p v e h e lt h p c communicate result highlyscientific registration event interest lifeyear gain patient trial transform complex datum layman term take boehringer ingelheim medication challenging order lose calculation assumption transparent sight overall picture big datum boehringer ingelheim scientifically sound initially hicap calculator set train development inhouse app boehringer ingelheim internal specialist health impact care patient hicap enable medical affair marketing hicap far measurement patient worldwide simply innovative gadget app translate highly help researchdriven pharmaceutical complex technical detail base clinical trial result company product commit team statistician drug sale datum break country easily datum expert take task result app understand graphic element show great convert abstract concept public benefit contribution boehringer ingelheim benefit accessible visual hicap calculator base patient health r shiny technology give estimate number prevent l g athe big picture g l n e e f r e g h eye big picture boehringer ingelheim science department found year ago future nobel prize winner heinrich wieland ensured futureoriented way today company scientific activity bundle innovation unit continue embody company spirit research scientist michael mark thing differently compare wieland time lot similaritie l g amichael mark notice bear wieland cousin thing straight away helene wife company founder give friendly albert boehringer onwards n eed welcome say look advise boehringer company day boehringer ingelheim champions development new medicine biberach germany upper swabian time age region yearold pharma believe mark start biberach cology graduate join research gifted chemist wieland push idea department boundary research plantbase feeling belong alkaloid develop cardiovascu want follow remain day mark say lar medicine cadechol boehringer respect lot happen ingelheim late lobelin company grow enor emergency treatment respiratory mously mark participate arrest shock condition countless research project advance conduct regular basic research head cardiometabolic student assistant research department university munich degree innovation unit hardly possible minute regret choosing boehringer medicine developer ingelheim ingelheim job appeal base company straight away exactly want able discover new mechanism action develop new medicine s appeal train pharmacist today mark responsible work researcher biberach people ridgefield connecticut usa organise research project internally partnership collaboration partner review idea forward work group withdraw staff project increase number substance look particularly promise boehringer ingelheim able work fundamental issue necessary foresight mark say time require responsibility spirit heinrich wieland last effect company science department celebrate centenary great chemist later nobel prize winner begin heinrich wieland right laboratory h g e r e e n l g adr michael mark staff evaluate digital image fluore cence laser microscope country differ edu cation expertise include special ist human medicine molecular biology employ gene analysis modern microscope access available scientific database probably soon able simulate effect effect software promise nascent discipline system biology regard research activity boehringer ingelheim build collaboration external partner university startup compa ny guest contribution ruipe xiao peke university mark come current field research thank phd supervisor wellknown pharmacologist hermann ammon working diabete start th century research young protg addition pursue academic doctoral study work career young chemist usually work mechanism insulin release advisor pharmaceutical compa boehringer ingelheim biberach ny order live external able mark directly link study lecturer wieland well initially focusse glinide connect integrate boehringer work substance class stimulate insulin ingelheim colleague secretion pancreas industry kind fundamental emerge repa glinide found father today researcher market prandin company include mark ssue protract phase mark think great heinrich colleague focusse lipid wieland today mark wish necessary metabolism atherosclerosis new engage find solution phase diabete research begin freedom straightfor fore ight project mark ward manner possible initiate search dpp inhibitors drug development complex substance inhibit involve different discus breakdown specific hormone pline regulation course intestine eventually lower blood necessary ensure patient sugar result work safety say mark hand active substance linagliptin trajenta researcher today naturally launch opportunity disposal bestselle medicine license novo nordisk team mark work scientist jointly market eli lilly company boehringer ingelheim portfolio l g athe significant medicine fact individual scientist mark work play major role wieland successor sglt inhibitor call jardiance georg scheuing develop entire active substance empagliflozin medicine practically read scientific article late long possible today occur mark phlori world mark say field research zin initially isolate simply big individual root bark apple tree lower blood topic complex make sugar level cause glucose specialist knowledge expertise excrete urine mecha necessary mark convince nism know long time today need champion mark team modern believe idea want use knowledge develop follow medicine treat diabete pharmaceuti currently colleague apply knowledge rare genetic working treatment compli mutation carrier cal research cation diabetes address excrete sugar urine know damage cause eye people mechanism constantly kidney vascular system apparent disadvantage accord possible want investigate ingly sglt inhibitor ask root cause diabete develop efficacious welltolerate long ment term say mark patient avoid disease disease expert sceptical team liver focus cardio able pursue idea jardiance metabolic research lipid metabo major success today lism play major role boehringer jardiance diabetes research isease need ingelheim step ahead er draw plantbase source mark believes look material wieland improve diabete glucose metabolism probably aware wieland isolation represent generation herapie bodys entire metabolic event boehringer ingelheim developer remain work natural active substance applica fundamentally unchanged good student georg scheuing wieland era boehringer ingelheim head science department tion close tie scientific community onwards guide company support basic research draw synthetic substance p ossible factor attract talented people major step forwards mark work company mark call colleague approach develop talent management support ment jardiance similar way promise young scientist supervise wieland time prepare new task idea substance work play active role international pursue application research network final diabetic patient modern pharma analysis different ceutical research constantly ask wieland regularly recommend patient good student promis disease need improved therapy ing scientist boehringer ingelheim application possible phd supervisor search therapeutic approach ernst boehringer young son knowledge disease company founder understand fundamental biological mechanism expertise arrive suitable molecule jointly market eli lilly company h g e r e e n l g afrom office biberach germany michael mark responsible work research colleague boehringer ingelheim heinrich wieland develop lobelin emer gency medication respiratory arrest shock condition phlorizin sglt inhibitor empagliflozin jardiance derive originally come root bark apple tree today diabete medicine jardiance great success l g athe right question f c u n p e n h g e r f e e n l gawhat kind project dr oliver reuss specifically study molecular biology work management dr reuss let exam consultancy complete ple currently work smart postdoc join addon classic stethoscope boehringer ingelheim small digital microphone fit inside initially stethoscope link work corporate business smartphone algorithm analyse analysis drive patient lung sound help strategy development doctor identify respiratory disorder forwards core business example idiopathic pulmonary fibrosis rare head business easily diagnose disease model health require early treatment care innovation not major technology company pioneer digital environ ment opportunity boehringer ingelheim expect product service boehringer dr reuss course s mega ingelheim future offer medicine hype field lot digital concept centre patient s idea address dr oliver reu huge selection sensor technology team doctor biologist enable patient measure instance blood pressure business manager blood sugar level simply ongoing basis approach involve blockchain order enable secure handle patient datum dr reu boehringer ingelheim work practice technology primarily consider technology outside financial sector context conventional medicine business dr reuss hand work bitcoin course artificial closely human intelligence huge topic dr reuss aim provide pharmaceutical therapeutic area patient comprehensive care define solution identify new field ve primarily need hand pharmaceutical company primarily provide medicine s way establish contact outside boehringer consider overall challenge treat illness year ingelheim innovative idea patient doctor healthcare increase focus come startup special partner system come develop service technology know accelerator contact ment new medicine put patient startup position identify potential centre thing offer gauge potential partnership solution develop additional benefit early way able partner additionally incorporate entrepreneurial spirit knowledge regulatory affair company context global presence absolutely necessary exciting boehringer ingelheim marketing new product venture fund recently receive additional core competence utilise fund digital healthcare concept competitive advantage l g aat general international signifi cance homeland scientific community grow considerably recent year china rank second research usa turn term number patent scientific publication international journal accord forecast trend set continue chinese government increasingly point invest resource promote science technology country graduate medicine tongji medical university wuhan standing sciences country good universi tie simply lack resource finance research clear recent decade china lead want achieve economic power country currently scientist leave homeland case lot outstanding research involve chinese researcher time thousands talented people like help shape future left usa europe order continue research teach chinese government increase research spending cent sustainable basis guest contribution ruipe xiao result situation today completely head institute molecular medicine different scientist peke university return home china usa specialized cardio vascular disease national institute aging develop treat lot people ask left ment strengthen heart muscle usa return china year heart attack example ago work basic research able continue research year senior investigator field peke university national institute aging nih time institute molecular medicine answer simple scientific conduct basic research research historical turning consume metabolic disorder look point china want consequence major disease history home country expensive type diabetes compli progress lead cation like high blood pressure decade search location planet high cholesterol peking university invite disastrous impact body achieve head new institute look way molecular medicine seize oppor treat complication marketable tunity accept institute basic research time research cardio metabolic consume expensive result disease regenerative medicine decade achieve market fact lead able result basic research institution world past medical breakthrough year difficult team university h g e r f e e n l gathankfully opportunitie pursue partner boehringer ingelheim costly necessary form peke university contract signing beijing research scientist foreground dr ruiping xiao stage need peke university dr clive support private sector wood head discovery research good research thank boehringer ingelheim fruitless fail reach people partnership strong industry partner come bring strength z near future thank partnership boehringer develop result make boehringer ingelheim access ready market research result help imple ingelheim find partner ment practice boehringer ingelheim time boehringer access peke university coopera ingelheim support peke university tion partner research way company currently research result borders programme finance postdoc position boehringer ingelheim promote highly help post pipeline promise research outside compa important financial nys traditional therapeutic area implement support wealth specialist exper strategic partnership primarily concern tise able draw par regenerative medicine currently practice ticipant research border project investigate different programme boehringer ingelheim topic cell regeneration example extensive expertise heart pancrea cancer research significantly joint research agenda cover topic enrich research cancer diabete research course career gene therapy researcher work project launch different partner world l g aboehringer ingelheim discovery research strategy border n n vat n c r e e b u l n u r h r n e n e r g e r e n g h e e r g n g c e n c e boehringer ingelheim unify scientific c ardiometabolic platform eg disease research establish research immune modula disease border border rbb team field tion fibrosis central nervous r egenerative discovery research team enable technolo system medicine employee base biberach gy mmunology icrobiome germany ridgefield connecticut ncology gene therapy r espiratory boston massachusetts usa diseases beijing shanghai china kobe japan vienna austria locations team boehringer ingelheim discovery research strategy base pillar cooperation peke university support goal harness emerge scientific development activity scouts search international bundle pillar research border infobox right discovery research scientific community promise strategy help boehringer ingelheim repeatedly originate innovation benefit patient company focus external partnership strength approach idea actively establish contact researcher external research institution industry easy research border university company simply team live work stand good research china familiar apparent success decade european american way work rbbs goal identify novel ultimately achieve major thank knowledge world scientific approach breakthrough overnight instead s outstanding mediator technology press quick result culture make cross company current therapeutic market profitably border communication easy rapid return investment aim future continue area future focus research work deepen expand cooperation area example regenerative condition addition example plan establish medicine gene therapy cultural hurdle company postdoc position microbiome research unable handle properly finance program meantime rbb conclude lead misunderstand ng think important partnership difficult researcher work benefit partnership precisely field basic society point china offer university scientific insti research important able scientist exceptional opportunity tute rbb plan communicate properly unambig moment position collaboration biotech uously boehringer ingelheim enable welcome company startup understand strategic returnee want miss partnership contact partner historic moment china h g e r f e e n l gai p r n f u h v e n q u e r e r c e n p l e e n h e e c n c u c h boehringer sohn ag co kg binger strae ingelheim germany telephone fax c n c corporate division communication public affair email pressboehringeringelheimcom internet wwwboehringeringelheimcom u e b c h boehringer sohn ag co kg c n c e p e g n n l u mpm corporate communication solution mainz wwwmpmde p h n l l u r n maskot plainpicture cover dieth schrder fotografie boehringer ingelheim michael alberstat masterfile istock shutterstock getty image istock alison romanczuk jovan vitanovski shutterstockcom august retroseso alamy stock foto laura adani stocksy set design eva jauss photo michael breyer p r n e b neue sddeutsche verlagsdruckerei gmbh ulm c p r g h c h boehringer sohn ag co kg right reserve annual report reproduce transmit form mean electronic photocopy permission write c h boehringer sohn ag co kg figure party annual report base datum avail able time financial statement draw upwwwboehringeringelheimcom annualreportboehringeringelheimcombb oo ee hh rr ii nn gg ee rr ii nn gg ee hh ee ii mm n n u l r e p r value innovationf n ci l h gh l ig h ts um ar r ep r amount million eur indicate change net sale region europe americas summary asia australia africa report business human pharmaceutical animal health biopharmaceutical sale discontinue operation research development expense personnel expense average number employee operate income operating income net sale group profitloss net sale group equity return group equity investment tangible asset depreciation tangible asset product human pharmaceutical product animal health net sale million eur change net sale million eur change spiriva nexgard na pradaxa frontline na trajenta jentadueto ingelvac ciroflex jardiance heartgard na newly aquire merial productso v e r v e w company shareholder perspective key aspect group management report consolidate financial statement product portfolio u r c p n improve health quality life patient goal researchdriven pharmaceutical company boehringer ingelheim focus disease satisfactory treatment option exist date company concentrate develop innova tive therapy extend patient live animal health boehringer ingelheim stand advanced prevention familyowne establish boehringer ingelheim pharmaceutical industry company employee create value innovation daily business area human pharmaceutical animal health biopharmaceutical boehringer ingelheim achieve net sale billion euro rd expenditure exceed billion euro correspond cent net sale familyowne company boehringer ingelheim plan generation focus longterm success shortterm profit company aim organic growth resource simultaneous openness partnership strategic alliance research boehringer ingelheim naturally adopt responsibility mankind environmentc n e n company shareholder perspective key aspect corporate body group management report information group report economic position risk report report expect development consolidate financial statement overview major consolidated company consolidate balance sheet consolidated profit loss statement cash flow statement statement change group equity note consolidate financial statement independent auditor report product portfolio human pharmaceutical respiratory disease cardiovascular metabolic disease oncology disease central nervous system infectious disease animal health livestock swine livestock cattle livestock poultry companion animal horse companion animal pet h e h r e h l e r p e r p e c v e christian boehringer chairman shareholders committee shareholder perspective gratitude satisfaction present boehringer ingelheim positive result annual report report proof reach patient human animal medicine positive contribution disease progression health past year structure position company undergo fundamental change work finish successfully complete fundamental task boehringer ingelheim primary objective remain maintain independence familyowne company time help people animal innovative medicine convince dedication commitment staff great value economic success clearly demonstrate come global focus initiative describe path innovation growth future time change upheaval particular give employee clear joint orientation motivation like expressly thank successfully step challenge past year energy commitment work achieve company goal sign christian boehringer chairman shareholders committee f c u u r joachim hasenmaier michael schmelmer hubertus von baumbach andreas neumann core leitbild independent familyowne intend remain create value innovation customer power people michel pairet allan hillgrove key aspect thank interest company please inform boehringer ingelheim progress past year hand concern annual report yearly financial statement hand like invite find accompany agility report successful year boehringer ingelheim growth business like highlight human pharmaceutical business show organic profitable distinctly abovemarket growth look sale figure stand patient different medical history boehringer ingelheim motivate desire important contribution health people animal generation boehringer ingelheim employee research develop manufacture innovative medicine positively change life patient invest relatively large sum research new medicine future set goal particularly human pharmaceutical business cent innovation patient relevant therapeutic approach mode action strategic decision lay foundation new period successful growth boehringer ingelheim focus longterm success sector digitisation mean sustained change particularly database industry like new bi x lab range initiative face challenge opportunity achieve great deal past year success reflect trust c ustomer like thank like thank partner accompa nie support journey past year special thank employee stand achieve face new challenge overcome dedication share passion make positive contribution innovation health people animal alike sign sign sign hubertus von baumbach joachim hasenmai allan hillgrove sign sign sign andreas neumann michel pairet michael schmelmer c r p r e b e shareholders committee board manage director christian boehringer hubertus von baumbach chairman shareholders committee chairman board manage director christoph boehringer dr joachim hasenmai corporate board division animal health erich von baumbach jr allan hillgrove isabel boehringer corporate board division human pharma dr mathias boehringer simone menne corporate board division finance prof dr dr andreas barner dr andreas neumann corporate board division human resource advisory board dr michel pairet corporate board division innovation egbert appel chairman advisory board michael schmelmer trustee martin hilti family trust corporate board division finance president hilti foundation kurt beck ministerpresident dr nikolaus von bomhard chairman board management mnchener rckversicherungsgesellschaft ag dr andreas kreimeyer member board executive director research executive director basf se jan rinnert chairman board management heraeus hold gmbh group management report boehringer ingelheim group management report consolidate financial statement product portfolio g r u p n g e e n r e p r information group report economic position risk report report expect development group management report information group boehringer ingelheim information group company group management report information group group business model researchbase pharmaceutical company boehringer human pharmaceutical form core boehringer ingelheim stand innovative medicine human ingelheim activity medicine boehringer ingel animal year heim long standard treatment respiratory world pharmaceutical company focus disorder cardiovascular disease metabolic disease familyowne company headquarters oncology disease central nervous system ingelheim germany research development immunology production sale pharmaceutical improve health quality life contribute great therapeutic benefit human medicine animal health area business human pharmaceutical animal health biopharmaceutical discontinue net sale business eur million operation activity boehringer ingelheim gen erate net sale eur billion human pharmaceutical employee worldwide start financial year exchange boehringer ingelheim consumer health care business animal health chc sanofis animal health business merial take place step represent successful completion strategic transaction begin december exclusive negotiation underline company biopharmaceutical consistent focus innovationoriente field follow successful completion transaction january boehringer ingelheim consumer health care business transfer sanofi return sale boehringer ingelheim receive sanofis animal health division merial change group consolidated compa discontinue operation ny number previous year comparable limited extent refer remark note financial statement consolidate financial statement product portfolio net sales region eur million heartgard frontline successfully incorporate company product portfolio establish swine vaccine ingelvac c ircoflex treat porcine circovirus type remain significant product animal health term net sale europe biopharmaceutical business important growth area boehringer ingelheim boehringer ingel asia heims biopharmaceutical activity comprise manu australia africa facture ownbrand marketable product america aaa actilyse metalyse praxbind process devel opment manufacture new biological entity nbe biosimilar world lead company process development commercial company big revenue contributor production biopharmaceutical thirdparty indus spiriva treat chronic obstruc trial customer tive pulmonary disease copd asthma pradaxa prevent stroke patient financial year boehringer ingelheim atrial fibrillation prevention achieve majority sale america treatment thromboembolic disorder trajenta europe region region asia j ardiance remain growth path australia africa aaa strategic significance treat type diabete significant group future growth make sale contribution boehringer ingelheim success fev big market usa japan germany newly introduce offer account sale year people rare fatal respiratory disease idiopathic pulmonary fibrosis ipf new treatment option research development rd achieve strong growth line mission statement boehringer ingelheim entrepreneurial goal research develop innovative business aim boehringer ingelheim continue medicine therapie treatment disease drive forward innovative development satisfactory treatment available exist product portfolio organic growth aim time major contribution cooperation external partner area need treatment high occupy boehringer ingelheim operate global research network leading position major indication area major facility biberach hanover ingelheim human pharmaceutical animal health germany ridgefield connecticut duluth georgia major emphasis development vaccine st joseph missouri usa vienna antiparasite pharmaceutical new approach austria lyon france therapy prevent detect treat chronic disease effectively animal health business unit second large animal health business worldwide follow boehringer ingelheim rely global research network merger boehringer ingelheim exist activity comprise facility country sanofis merial business product nexgard world cooperation public research group management report information group boehringer ingelheim research development expenditure eur million net sale human pharmaceutical expenditure eur million human pharmaceutical net sale average number employee investment tangible asset investment infrastructure eur million institution academic institution biotech com boehringer ingelheim rd activity basis panie research effort supplement company sustainable success innovative capa cooperation licence agreement field bility play key role group positive business development project technology company development past year supplement exter enter agreement field oncol nal cooperation partnership inhouse rd ogy focus highly innovative research approach continue priority future include partnership siamab therapeutic abexxa biologic cooperation aca financial year employ average demic centre vanderbilt university university people rd facility total eur california sarah cannon research institute billion invest rd new medicine partnership gubra dicerna add compa correspond group net sale nys development portfolio area metabolic level expect disease company enter new partnership alliance field respiratory disorder human pharmaceutical disease central nervous system cns century commit improve life people live respiratory disease aforementione partnership key component scientific research field important boehringer ingelheim innovation strategy sup boehringer ingelheim year initiate plement highly comprehensive development portfo clinical trial announce new datum help lio external partnership boost innova increase therapeutic option patient tive capability rd evidence doctor condition focus chronic boehringer ingelheim solid successful coopera obstructive pulmonary disease copd idiopathic pulmo tion external innovation leader nary fibrosi ipf systemic sclerosis interstitial lung disease sscild progressive fibrose intersti july boehringer ingelheim establish digital tial lung disease pfild laboratory bi x independent subsidiary serve platform innovation function data new subanalyse tonado otemto trial science agile software development user experience spiolto tiotropiumolodaterol r espimat design cooperate exclusively boehringer ingel present european respiratory society er heim business area develop goingtomarket health international congress september innovation human medicine animal health base new assessment copd patient accord global initiative chronic obstructive lung disease gold guideline subanalyse confirm consolidated financial statement product portfolio tiotropiumolodaterol provide significant benefit offer opportunity patient tiotropium monotherapy placebo term eligible participate clinical trial symptom reduction quality life result prove copd patient benefit dual bronchodilation senscis trial safety efficacy nintedanib tiotropiumolodaterol early disease systemic sclerosis example ongoing commitment improve life patient live recently publish gold report recommend rare disease end year recruitment dual bronchodilation longacte anticholinergic trial complete patient lama longacte betaagonist laba recruit large global prospective clinical trial substance class spiolto respimat firstline sscild date treatment option symptomatic copd patient gold group bd boehringer ingelheim strongly commit oncology lead scientific discovery patient obstructive respiratory disease broad research development programme cancer cell important medication deep direct agent immune oncology therapy lung inhaler play important role combination successfully advanced therapy r espimat innovative inhaler research programme focus deliver firstinclass actively deliver unique mist mean person treatment breakthrough potential need slow deep breath medication strengthen oncology portfolio company estab deep lung patient experience survey lishe series important partnership strategic show majority patient consider respimat collaboration world lead academic easy use industry advocacy organisation research drive startup company commitment innovation result injourney trial investigate result important treatment lung safety tolerability profile nintedanib combina cancer tion pirfenidone treat idiopathic pulmonary fibrosis ipf publish september afatinib g iotrifgilotrif secondgeneration american journal respiratory critical care medi medicine treatment specific type nonsmall cine ajrccm result combination cell lung cancer nsclc patient metastatic nsclc nintedanib pirfenidone result manageable squamous histology available patient safety tolerability profile majority patient certain country receive approval giotrif china product march enrol patient standard care market approve indica inbuild trial double blind randomize placebo tion additionally boehringer ingelheim initiate control trial evaluate efficacy safety giotag realworld study investigate treatment nintedanib week patients progressive sequence cancer cell direct therapy extend fibrose interstitial lung disease pfild study chemotherapyfree treatment time patient investigate efficacy safety nintedanib study include patient start treatment range progressive fibrose lung condition afatinib standard clinical practice follow idiopathic pulmonary fibrosis ipf approach thirdgeneration medicine realworld study build enroll patient different fibrose lung disease comprehensive luxlung trial programme trial exhibit progressive fibrose behavior afatinib include trial include direct head head randomize trial versus firstgeneration treatment group management report information group boehringer ingelheim boehringer ingelheim second cancer drug market initiate start recruitment second vargatef nintedanib treatment advanced quarter boehringer ingelheim eli lilly company nonsmall cell lung cancer nsclc approve und announce plan initiate additional new trial launch market worldwide empagliflozin treatment people chronic phase ii datum lumemeso trial study kidney disease trial enrol participant effect nintedanib mesothelioma rare aggre diabete start sive cancer strongly associate asbestos con tact show nintedanib combination stand trajenta linagliptin dpp inhibitor boehringer ard chemotherapy prevent tumor continue ingelheim thirdbiggest product register strong grow halve risk disease progression growth cardiovascular outcome study result meaningful patient carmelina carolina continue plan currently treatment option available key result carmelina expect pub condition datum phase iii trial nintedanib lishe j ardiance trajenta mesothelioma expect available jointly market boehringer ingelheim eli lilly company boehringer ingelheim large therapeutic area cardio vascular metabolic disease achieve anticoagulation space see publication strong growth boehringer ingelheim continue important phase iii study pradaxa inv area dabigatran etexilate praxbind idarucizumab highly recognise international congress study company continue supplement regulatory simultaneously publish prestigious new product information jardiance empagliflozin england journal medicine march result sglt inhibitor worldwide order reflect datum recircuit trial atrial fibrillation patient undergo risk cardiovascular disease result ing ablation present american college landmark empareg outcome study number cardiology scientific session datum show signifi prescription increase continuously course cantly reduce major bleeding rate compare warfarin sale eur billion j ardiance ablation procedure study provide highly reach blockbuster status product relevant datum electrophysiology specialist frequently prescribe sglt inhibitor patient july final result reverse ad new brand prescription time j ardiance study praxbind idarucizumab present oral antidiabetic drug market datum international society thrombosis haemo label support use reduce risk cardio stasis biennial congress datum show p raxbind vascular death people type diabete estab immediately reverse anticoagulant effect lishe cardiovascular disease addition j ardiance pradaxa patient emergency situation set apart inclass competition safety august result redual pci study atrial new datum present course fibrillation patient follow percutaneous coronary ing increase risk lowerlimb amputation lla intervention stent placement present bone fracture development empagliflozin european society cardiology congress p radaxa additional disease area ongoing quarter combination single platelet inhibitor lead emperor sister trial emperor highly significant reduction bleeding rate reduce emperor preserve aim inve compare standard care warfarin therapy tigate empagliflozin treatment people combination dual platelet inhibition addition chronic heart failure diabetes number analyse base datum routine clinical consolidated financial statement product portfolio practice publish include new result biopharmaceutical gloria aftm registry publication biopharmaceutical bring significant change confirm establish safety profile pradaxa treatment disease severely restrict patient live chronic disease hospital participate frequent health care system expose increase angel initiative improve acute stroke care europe financial pressure relation treatment lead european stroke introduction biosimilar improve sustaina organisation eso common goal optimise stroke bility health care system allow patient treatment save life benefit biologically produce medicine boehringer ingelheim develop biosimilar oncology animal health immunology goal provide therapy rd work field animal health boehringer option provide genuine value patient ingelheim traditionally concentrate innovative vac therapeutic area cine protection livestock pet pharmaceutical product treatment chronic cyltezo boehringer ingelheim biosimilar humira disease core area strengthen adalimumab approve usa companys acquisition merial begin eu treatment chronic inflammatory ning supplement pillar autoimmune disease adult child approval antiparasitic base comprehensive package datum document biosimilarity cyltezo humira facilities europe asia oceania north adalimumab accord analytical pharmacological central south america focus research new nonclinical clinical data cyltezo available drug development future therapeutic solu europe usa present boehringer ingelheim tion vaccine base local pathogen abbvie currently involve patent litigation pathogen variants imperative present usa key market region local rd production facility past year invest approximately bi boehringer ingelheim biosimilar candidate eur million new rd plant expansion avastin bevacizumab drug treatment exist facility investment demonstrate advanced stage cancer late phase clinical commitment strengthen animal health mean development innovative preventive medicine intention sus tainably strengthen lead position field production human pharmaceutical initiate clinical study world task human pharmaceutical production wide register patent receive reliable market launch product supply authorisation addition internal research patient highquality pharmaceutical development rd analyse external project competitive cost boehringer ingelheim make use product integrate portfolio global network comprise facility contract appropriate obtaining approval expand manufacturer supplier purpose able geographical distribution exist product react flexible manner continually evolve important aspect rd activity demand modern production network company launch strategy volume value late currently gradually roll plan group management report information group boehringer ingelheim undergo continuous development animal health value chain subsequent acquisition merial boehringer ingelheim animal health operating network past year boehringer ingelheim operate plant facility country comprise site manu country plant manufacture pharmaceutical facture vaccine pharmaceutical product produce important chemical active nutraceutical industrial setup complement substance boehringer ingelheim production contract manufacturer primarily north central facility medical product production facil america europe define new itie manufacture product particular relevance network strategy order balance internal exter group manufacturing technology require nal production subsequently integration merial unique expertise production capacity focus core product alignment busi appropriately supplement strategic partnership ness requirement invest globally foot contract manufacturer partner primarily focus mouth disease research capacity start manufacture product advanced stage consolidate relevant network china taizhou life cycle facility successfully obtain gmpcertificate past year important investment approve biopharmaceutical particular ingelheim germany headquarters boehringer ingelheim pursue biopharmaceutical fornovo italy sant cugat spain yamagata activity facility biberach germany vienna japan facilities ingelheim facility make austria fremont california usa shanghai china progress transformation goal focus comprise manufacture ownbrand marketable initial market supply process future product actilyse etalyse p raxbind fornovo strengthen term role ensure manufacture new biological entity nbe routine supply chemical active ingredient biosimilar clinical testing globally network sant cugat expand exist product port lead company process development com folio include respimat technology investment mercial production biopharmaceutical thirdparty yamagata intend meet need japanese industrial customer pharmaceutical patient longterm basis local level company client boehringer ingelheim biophar maceutical business boehringer ingelheim cover volume value strategy intend opti entire biopharmaceutical value chain genetic mise underlie business process bring development cell follow manufacture great focus production network boost active substance filling finish pharmaceutical flexibility process standardise product product launch global mar continuously optimise term benefit ket supply business implement way system stepbystep process chain endto comparison previous year see overall end core element active management increase use capacity network product througho ut life cycle optimisation industrialscale production facility boehringer ingel inventory worldwide implementation heim volume production meet continuously ris highp erformance global logistic distribution strategy ing demand actilyse particularly chinese market company facility fremont california usa successfully approve fda ema authority market production bio similar consolidated financial statement product portfolio cyltezo furthermore largescale plant technical support regular ehss audits biberach successfully complete registration process boehringer ingelheim internal facility prem customer product submission ise supplier contract manufacturer ensure com application approval authority expansion pliance international stand project new industrialscale biopharmaceutical produc ards eg pharmaceutical supply chain initiative tion facility boehringer ingelheim site vienna supplier code conduct apply relevant supplier austria reach milestone foundation supplement programme status environ facility lay summer company mental protection occupational safety continuously commercial facility shanghai china success review potential improvement identify fully operation gmp hospital material basis addition company address important produce deliver study china current social issue relevance boehringer country schedule ingelheim implementation sustainability goal important consult closely stake occupational safety environmental holder company outside protection progress relation key issue take protection employee facility stand formulate relate position paper striv environment sustainable use natural ing achieve continuous improvement area resource promotion environmental awareness sake company sustainability major component company mission state ment prime importance boehringer ingelheim boehringer ingelheim commit support un compliance social environmental aspect sustainable development goal sdgs make firmly anchor corporate philosophy contribution sustainable future rd un year ensure achieve sustainability climate change conference bonn conference future generation party cop ehss representatives boehringer ingelheim participate year company establish groupwide bind standard term environmental protection contribution reduce global co e emis health safety work internal guideline reflect sion set goal reduce respective countryspecific requirement case entire co emission compare far standard prescribe law value particular follow international standard guid ance document work close cooperation health safety employee high priority relevant association boehringer ingelheim cor boehringer ingelheim reflect interna porate department environment health safety sus tional safety standard safety culture tainability ehss responsible strategic focus practise rollout groupwide safe ini tiative aim reduce number work boehringer ingelheim characterise place accident continue successful workshop integration sanofis animal health division merial hold focus behaviourbased safety group ensure compliance ehss duty care environmental risk assessment imple employee report mente new facility integration audits boehringer ingelheim employ people initiate standard align process har worldwide represent increase monise group management report information group boehringer ingelheim report economic position previous year boehringer ingelheim increase num professional company backdrop demo ber staff region graphic change young professional start career boehringer ingelheim germany average number employee region different scientific technical commercial america field young people enrol europe training programme asiaaustraliaafrica aaa company aim strengthen appeal boehringer ingelheim employer current major success factor positive growth group future employee boehringer ingelheim motivate reliable staff accordingly par recipient award effort area ticularly commit actively develop support receive mark auditor employee order well prepare chal international independent employer institute lenge ahead comprehensive training relation key area staff planning performance system set great store acquisition management career succession plan technical expertise promote social skill compensation benefit receive distinction facility germany facility integration experience cultural china taiwan brazil russia spain poland grounds personality boehringer ingelheim create number country award rating openness different approach opinion live unprecedented evidence strong appeal corporate vision value innovation development opportunity company global company important diver employee potential recruit sity market reflect workforce create work environment embrace diversity differ social responsibility ence pillar corporate culture take social responsibility important aspect boehringer ingelheim contribute factor corporate culture commitment wellbeing company success patient employee family focus range project addition support people need addition competitive salary boehringer ingelheim initiative country region offer benefit employee include active company company activity range company pension plan flexible homebase focus protect maintain environment work option numerous healthrelate benefit significant segment corporate strategy previous year boehringer ingelheim continue talent management department remit ensure assist provide support integration people employability staff promote wide range oppor flee home country migrant tunitie innovation work motivate employee crisis region pursue broad range measure nurture talent develop individual area boehringer ingelheim employee germany conduct integration workshop state centre vocational training major importance asylum seeker ingelheim addition mid boehringer ingelheim understand company pursue partnership deutsche social responsibility company offer career opportunity universittsstiftung partnership boehringer great number young people time ingelheim sponsor welcome scholarship pro tie talented wellqualified workforce young gramme support student crisis region consolidate financial statement product portfolio company help candidate crisis region lecturer learn socially entrepreneurial area people flee join company offer think practical activity development ing apprenticeship opportunity complete social entrepreneurship project introductory training year internship boehringer ingelheim value respect employee major pillar social commitment make difference actively promote diverse cooperative health mmh initiative start open work environment conscious develop social entrepreneurship movement fact diversity market customer company externally socially com reflect workforce diversity make mitte sustainable activity limit individ right mix inclusion bring ual project relate region issue instead good result mix focus encour initiative focus connect local inter age inclusive environment kind diver national partner different sector network sity thrive boehringer ingelheim participate traditional visible invisible border cen th german diversity day motto diversity tral element successful social movement order company large german facility ingel identify promote implement innovative solution heim biberach official member farreache complex challenge healthcare diversity charter early sector cocreation bridge social com mercial entrepreneurship bring social entrepre neur nonprofit organisation health care report economic sector boehringer ingelheim employee position resource date mmh network boehringer ingelheim ashoka world large non profit organisation help macroeconomic environment social entrepreneur reach million people growth global economy area healthcare robust form usas increase protec tionism brexit vote source internally mmh feature boehringer ingelheim economic uncertainty significant negative impact hr development activity year market growth volume world trade change understand emerge market initi pace global gross domestic product growth ative support executive residence eir time europe economic recovery continue mmh insight india staff development programme large country achieve strong growth network partnership nonprofit organi rate past year pre vious year nonethe sation social enterprise healthcare sector eurozone continue burden huge programme young professional opportu structural weakness member state picture nity support participant project facility emerge economy mix growth turkey certain period time jointly develop project decline significantly political conflict improve health mean understand peo country brazil russia track ple environment everyday challenge growth spend past year recession par offer solution need health aware ticularly account decline crude oil price ness affordability accessibility health service acceptance play key role mmh play role growth pick japan buoy expansionary university sector goal help student fiscal monetary policy increase export group management report report economic position boehringer ingelheim pin investment rise wage private household apparent sector overall term decline unemployment stimulate consumer economic upturn continue price adjust gross spending willingness invest usa mone domestic product growth expect export tary environment remain favourable despite maintain clear upward trend drive improved interest rate hike implement american central economic outlook eurozone rest world bank level inflation moderate additional budget cost likely resolve follow formation new german government growth expect world region global growth level predict risk sur consumer price increase rapidly crude oil rounding growth europe continue include possi food price pick considerably price ble consequence brexit negative effect increase past year close result intensify international competition target inflation rate european central bank field taxation america tax reform ecb euro currency area despite slight usa likely additional stimulating effect overutilisation tension area economy economy stabilisation oil price encour sign overheat germany age fresh investment energy sector addition euro major currency china high level growth expect boehringer ingelheim group dollar usd slightly weak previous japanese yen jpy dollar fluctuate year large emerge economy likely pick usdeur january usdeur growth stabilise commodity price december reach low usdeur sep tember japanese yen remain volatile germany economy benefit broad euro usual end year euro pick base upward trend reflect low japanese yen rate jpyeur unemployment rate year lively consumer reach low jpyeur midapril demand private household coun try european central bank low interest rate pol global pharmaceutical market register growth icy stimulate demand construction investment financial year trend drive influx refugee trigger growth rise demand industrialise country cancer level government consumption spend adjust medicine product treatment autoimmune low number work day country gross disease antidiabetic medicine age domestic product increase government finance population industrialise country industry register significant surplus despite expansionary growth remain stable albeit slightly weak spending policy solid economy decline interest previous year development relate struc payment reduce ratio debt tural problem eurozone emerge country country gross domestic product lead decelerate growth demand general increase supply constraint labour course business market heavy use capacity somewhat longterm sustainably successful development form limit opportunity growth rise level basis securing company independence employment set drop low level long term combine stable earning sound immigration process demographic change finance core boehringer ingelheim aggravating scarcity skilled worker consolidate financial statement product portfolio strategic focus previous year base approach overall sale growth exceed expectation support principle good result clinical trial able place promise new product market successfully year characterise significant change push ahead wellestablishe product boehringer ingelheim change hand experience increasingly difficult market represent important step company future situation constantly challenge market access completion exchange consumer health care grow price pressure key market overall business sanofis animal health business merial company assert despite difficult con turn year big change dition lay foundation future growth past year transaction significantly improve market position field animal health boehringer ingelheim record operating income establish large global player eur million corresponding return sale segment percentage point previous year return sale operating income include boehringer ingelheim record net sale eur mil significant positive eur million negative lion financial year correspond eur million extraordinary effect mainly increase compare previous year figure associate exchange business area sanofi eur million exchange rate development despite negative impact amount eur mil foreign exchange market associate exchange lion operating income increase eur million rate effect slight impact currency adjust absolute term result positive sale growth boehringer ingelheim growth rate stand financial income negatively affect interest sale eur million america region effect pension similar liability hold represent total sale remain ing income reduce impairmennt relate big market boehringer ingelheim strong company income taxis slightly increase sale previous year mainly higher previous year purchase merial europe region like wise register strong sale growth reach key figure eur million change eur million accordingly previous year net sale group sale achieve region operating income asia australia africa aaa region register return net sale growth currencyadjuste sale increase boehringer ingelheim realise revenues eur mil lion region corresponding share tax expense influence significant extra group total revenue ordinary effect tax expense current period include tax expenditure disposal company consumer health care business usa net sales region currency eur million change adjust tax reform approve december america tax cut job act require revaluation europe defer tax asset liability base corpo asiaaustraliaafrica rate income tax rate enact law balance aaa sheet date future financial year likewise significant negative impact tax expense group management report report economic position boehringer ingelheim overall boehringer ingelheim record positive ingelheim able assert difficult development operating business environment lay foundation fur financial year despite negative onetime effect relate ther growth integration merial animal health business sale consumer health care business previous year piriva treat chronic far high tax payment company obstructive pulmonary disease copd history effect connect tax reform big contributor sale achieve boehringer ingelheim group end year revenue eur million reporting period group loss eur million group profit slightly previous year level eur million eur mil lion europe particular sale spiriva decline significantly increase earning position level generic competition account loss past financial year boehringer ingelheim business relevant patent activity divide human pharmaceutical ani mal health biopharmaceutical consumer health second big sale contributor boehringer care business sell sanofi january ingelheim anticoagulant pradaxa record sale report discontinued operation eur million correspond increase include production service level complete scope transfer business sanofi eur million medicine j ardiance treatment type diabete achieve sale net sale business currency excess billion euro time eur million change adjust human pharmaceutical animal health net sale eur million change biopharmaceutical spiriva sale pradaxa discontinue operation trajenta jentadueto jardiance human pharmaceutical regard regional distribution sale usa total revenue human pharmaceuti share far large cal main pillar boehringer ingelheim business market boehringer ingelheim generate sale activity revenue amount eur mil eur million correspond increase lion equivalent change cur compare previous year currency rency adjust compare previous year adjust increase volume price drive positive sale growth trend result particular successful placement innovative product secondbigg market europe account solid market position establish medicine revenue eur million sale decrease emerge market market key growth compare eur million exchange driver continue experience increase rate effect significant influence price pressure particularly establish medi sale trend europe price pressure piriva cine major market overall boehringer decline sale establish brand impact consolidate financial statement product portfolio biopharmaceutical net sale region eur million change sale biopharmaceutical contract manufac usa ture amount eur million represent europe growth compare previous year emerge market japan presentation expenditure income cost material higher previous emerge market sale increase year eur million come eur mil eur million currency adjust sale lion represent cost material ratio previous year amount eur million personnel expense amount eur million expiry patent icardis sale japan correspond personnel cost ratio decrease eur million increase percentage point low previous year level sale product unable compensate effect line expectation depreciation amortisation record increase eur million eur million animal health operating expense rise compare pre revenue products animal health business vious year come eur million increase eur million past financial year item cost category include commission licence acquisition merial activity correspond payment dependent sale increase previous year currency adjust operating income higher previous year eur million come eur million net sale eur million change influence significant positive considera nexgard na bly high negative extraordinary factor onetime frontline na effect particularly relate exchange business ingelvac circoflex areas sanofi reversal provision adjust heartgard na extra ordinary effect operate income considerably higher previous year group region benefit sale exceed expectation growth bestselle product include product merial group nexgard frontline reporting period financial income amount heartgard eur million eur million compare year mainly interest effect net sale region result pension similar obligation hold eur million change income decrease particular impairment usa loss relate company investment europe metasia despite decrease financial income hold latin america inome income taxis amount eur mil lion eur million high product ingelvac c ircoflex achieve previous year tax expense influence sig sale growth sale eur million achieve nificant extraordinary effect tax expense cur growth rate compare previous year rent period include tax expenditure disposal group management report report economic position boehringer ingelheim risk report company consumer health care business approve relevant committee standardised usa tax reform approve decem process ber tax cut job act require revaluation defer tax asset liability base investment particular importance boehringer corporate income tax rate enact law ingelheim strategic point view continuous balance sheet date future financial year like investment requirement longterm development wise significant negative impact tax expense company form basis profitable growth business activity note regard provision german commercial law shareholder personal taxis total eur million invest tangible arise group business activity recog intangible asset year review nised tax expense instead taxis present withdrawal group equity take april groundbreaking ceremony take place extraordinary effect account actual tax ratio expansion biopharmaceutical production vienna markedly high figure show profit austria investment volume eur mil loss statement lion include infrastructure measure big single investment boehringer ingelheim company overall despite positive business development tory new job create significant increase operating income significant facility decade boehringer ingelheim group end year con solidated loss eur million consolidated new biopharmaceutical production facility profit eur million far high tax open shanghai china new job payment company history effect con create initial investment phase necte tax reform eur million invest project facility date bio financial position pharmaceutical cell culture production facility launch boehringer ingelheim financial management instrument lead international biopharmaceutical manufac method aim secure liquidity minimise turer china global network biopharmaceu financial risk optimise cost capital tical production facility biberach germany vienna appropriate capital structure financial activity austria fremont california usa shanghai gear support business strategy china boehringer ingelheim contract manufacturing business boehringer ingelheim bioxcellence global company exchange rate volatility sig place supply innovative product reliably meet nificant impact boehringer ingelheim financial strong rise demand biopharmaceutical formance importance business industry china worldwide associate supply relationships mean exchange rate development dollar constitute great cash flow operating activity amount individual risk framework groupwide eur million despite significantly financial report foreign exchange risk calculate high operating income represent slight decline generally hedge derivative financial eur million contrast provision instrument nature scope measure release operating income previous year set group guideline regularly discuss include increase provision cash flow invest ment eur million mainly impact consolidated financial statement product portfolio cash settlement exchange business area provision high pre sanofi tax payment result sale vious year amount eur million account consumer health care business cash outflow payable loan increase past year financing activity eur million mainly include total eur million repayment financial liabiltie merial company previous hold company sanofi overall status show financial position remain take consideration exchange effect change resoundingly positive balance sheet group consolidate company lead respective balance sheet ratio sum boehringer decrease boehringer ingelheim group financial ingelheim net asset financial earning position fund eur million eur million confirm credential soundly finance profitable company net asset financial year boehringer ingelheim total risk report asset amount eur million increase eur million compare previous year acquisition merial tangible risk opportunity management intangible asset amount eur million aim risk management system implement boehringer ingelheim identify businessspecific end year financial investment amount risk particular risk jeopardise continue eur million correspond decrease existence company early possible assess eur million previous year value inventory reduce reasonable level mean show growth eur million trade suitable measure receivables rise eur million eur million liquid fund include security current assess risk context holistic risk asset stand eur million previous year management endeavour account eur million result opportunity opportunity management base strategy objective company view aforementioned change group equity individual business operate business unit amount eur million cover value integral groupwide planning manage group tangible intangible asset addition ment system responsible business equity pension provision longterm account function bear direct responsibility early sys payable loan available group tematic identification analysis use opportunity long term total item amount boehringer ingelheim researchdriven inno eur million represent share vative pharmaceutical company current research total asset consequently longterm dispos development activity naturally consider relevant able capital cover intangible tangible asset opportunity relevant project illustrate trade receivables research development chapter difference capital consolidation increase person responsible key business func eur million eur million exclusively tion include process calculate assess drive exchange consumer health care busi ing risk groupwide risk information system ness sanofis animal health business ensure identify risk analyse assess carefully follow appropriate classification group management report risk report boehringer ingelheim category adequate countermeasure initi credit countryspecific risk ate implementation consistently monitor boehringer ingelheim expose credit countryspecific risk result international busi year review internal auditing perform ness activity portfolio trade account target routine audits extraordinary audits receivable trade account payable identi world addition compliance legal fied extraordinary risk group requirement internal group guideline main usual level sector apply possible focal point functionality system effec default risk receivables largely hedge tiveness internal control prevention loss economic political risk continue asset efficiency structure process carefully track credit countryspecific risk corresponding adjustment optimisation initi position respond negative change timely manner ate necessary risk regard concrete individual risk financial investment shareholding risk important risk boehringer ingelheim group pursue defensive investment strategy expose break follow specific cate management financial asset reflect gorie financial risk legal risk production environ orientation portfolio focus european mental risk personnel risk industryspecific risk economic monetary union emu government bond credit rating shortterm investment risk identify concrete select bank result concrete appear controllable mean specific manage controllable risk major financial invest ment procedure term abstract case ment net book value strategic inv risk completely control ment relate company affect market mean target management procedure regardless business circumstance lead high vola probability occurrence tility fair market value specific risk cover respective impairment consolidate financial risk financial statement relevant financial risk break follow currency risk credit countryspecific risk legal risk financial investment shareholding risk business activity group expose legal risk distinction regulatory liability currency risk patent protection risk global orientation business activity result currency risk exchange rate volatility particularly regulatory risk regard dollar japanese yen group boehringer ingelheim expose risk arise legal monitor quantifie risk regular interval dispute proceeding official investigation make predictable future business mean legal administrative decision ongoing future relevant hedging strategy appropriate financial proceeding predict regard resultant instrument forward exchange contract risk abstract resultant risk subsequently designate con crete controllable liability risk marketing sale pharmaceutical expose potential product liability risk boehringer ingelheim consolidate financial statement product portfolio currently product liability insurance cover com risk area environment health safety pany risk profile absolutely guarantee sustainability ehss preemptively minimise insurance coverage maintain ensure global compliance high safety stand reasonable cost acceptable condition suf ard appropriate emergency plan draw ficient protect boehringer ingelheim claim possible incident kind practise loss potential claim loss case subject comprehensive quality test regular foreseeable product liability insurance interval result measure risk part cover specific liability risk remain class concrete risk exposure cover provision personnel risk furthermore product liability claim tie sub boehringer ingelheim company expose stantial financial resource management capacity demographic change resultant risk detrimental company image event affect lack appropriately qualified personnel market consider product unsafe ineffec potential risk substantial impact tive result unexpected effect regard company business activity risk abstract include longterm planning process year gain strategic significance result patent protection risk boehringer ingelheim counter risk mean protection innovation trademark brand comprehensive personnel concept regardless patent right particular importance boehringer ethnic background gender religion offer com ingelheim research company commercial pro pany employee development opportunity base tective right increasingly target attack vocational skill social expertise personal aptitude breach take necessary precaution allow willingness responsibility accordance detect threat early stage commencing need company view counter appropriate countermeasure defend legal position measure describe risk regard concrete legal mean available risk regard concrete industryspecific risk boehringer ingelheim expose business risk spe production environmental risk cific pharmaceutical industry risk quality management system compliance process materialise past financial year increase continuously optimise close cooperation significance result impact boehringer relevant authority order ensure compliance ingelheim continue class abstract cgmp standard current good manufacturing practice risk area continue high significance addition loss exclusivity product estab group classify abstract lishe market risk associate devel opment registration new product risk order guarantee supply product increasingly include change restrictive requirement market implement measure guarantee relate pricing reimbursement sale reliable highquality supply internal exter market frequently price pharmaceutical product nal customer addition supplier management subject state monitoring regulation procurement involve build internal price pressure cheap generic drug standby capacity result risk concrete cause state reimbursement system boehringer group management report risk report boehringer ingelheim report expect development ingelheim keep close eye growth innovation continue change sale market take appropriate meas successful market future regard ure response current development change healthcare system increase price pressure particularly wellestablishe medicine overall statement risk situation major market regard increase current perspective aware risk challenge market access new product conjunction risk lead expect low growth impetus pharmaceutical indus lasting impairment company asset financial try come year boehringer ingelheim assert earning position jeopardise continue despite difficult condition existence boehringer ingelheim lay foundation growth presume revenue continue grow report expect slightly comparable basis ie discontinued development operation research development expense remain high year review intense line strategy drive growth pro challenging time boehringer ingelheim mote new product future primarily product lay foundation sustainable development research development facility longterm growth company major invest area care close investigation decision therapeutic benefit associate prospect success comprehensive portfolio prospective consistent focus business innovation product promise study outcome orient field attest strategic exchange newly approve product significant sale potential sanofis animal health business merial boehringer justify high level investment research ingelheim consumer health care business contract development envisage slight increase exchange sign june trans investments research development new action successfully close january pharmaceutical transaction improve competitiveness animal health business industry important addition patent expiry attack patent growth market enable offer customer major challenge face researchdriven pharmaceu worldwide innovation add value tical industry increase investment high level pool complementary product rd big hurdle increase cost associ portfolio merial boehringer ingelheim exist ate product approval context e technology platform vaccine anti parasitic increase cost pressure healthcare system pharmaceutical speciality product particularly emphasise lead decrease willing ness adequately recognise large amount invest increasingly difficult market environment increase development new medicine result unpredictability business pose major challenge significant price pressure major market pre entire pharmaceutical industry continue scription medicine conjunction long plan require significant attention boehringer ingelheim development cycle new product make regard competitiveness business predictable require recognise important retain scope seize opportunity quickly hand sub consolidate financial statement product portfolio jecte cost strategy continual monitoring adjustment hand end launch initiative past year accelerate reaction change reduce organisational complexity low cost base order create potential investment secure com pany longterm success difficult market envi ronment hand potential result measure introduce promis ing new product launch hand plan operating income comparable basis slightly year level familyowne company boehringer ingelheim pri mary aim maintain firm independence com petitiveness longterm sustainable organic growth take precedence shortterm profit tar get confident achieve ambitious target thank great innovative strength base comprehensive portfolio prospective product global presence support highly qualified motivated employee current product launch expansion emerge market boost growth area business stand vision value innovation research develop innovative product offer high medical benefit bring market result effort provide new medicine enable doctor treat patient novel therapy effectively consolidate financial statement boehringer ingelheim consolidate financial statement product portfolio c n l e f n n c l e e n overview major consolidated company consolidate balance sheet consolidated profit loss statement cash flow statement statement change group equity note consolidate financial statement independent auditor report overview major consolidated company boehringer ingelheim overview major consolidated company c h boehringer sohn ag co kg boehringer ingelheim boehringer ingelheim boehringer ingelheim vetmedica gmbh europe gmbh international gmbh australia r germany p r austria p r austria r boehringer ingelheim animal health boehringer ingelheim boehringer ingelheim rcv forschungsinstitut fr molekulare australia pty ltd north ryde pharma gmbh co kg gmbh co kg vienna pathologie gesellschaft mbh ingelheim vienna boehringer ingelheim brazil p r boehringer ingelheim gmbh pharma gesmbh vienna ingelheim belgium merial saude animal ltda boehringer ingelheim paulo microparts gmbh dortmund czech republic scs boehringer ingelheim comm v brussels boehringer ingelheim boehringer ingelheim spol ro china p r biopharmaceutical gmbh prague ingelheim china p merial animal health co ltd boehringer ingelheim veterinary nanchang finland boehringer ingelheim research center gmbh co kg international trading shanghai hanover boehringer ingelheim co ltd shanghai denmark p r finland ky espoo merial norden hoersholm philippines norway boehringer ingelheim france p r boehringer ingelheim phil inc manila norway ks asker merial sas lyon usa p r poland italy p merial inc duluth georgia boehringer ingelheim sp z oo merial italia spa milano warsaw merial select inc gainesville georgia japan r boehringer ingelheim animal health japan co ltd tokyo puerto rico p merial barceloneta lcc barceloneta united kingdom p merial animal health ltd harlow distribution p production r research development sole personally liable manage shareholder boehringer ag product portfolio c h boehringer sohn grundstcksverwaltung gmbh co kg boehringer ingelheim auslandsbeteiligungs gmbh argentina r france p netherlands p taiwan boehringer ingelheim sa boehringer ingelheim boehringer ingelheim bv alkmaar boehringer ingelheim buenos air france sas paris taiwan ltd taipeh boehringer ingelheim animal health operation bv alkmaar australia greece p thailand boehringer ingelheim pty ltd boehringer ingelheim ellas ae new zealand boehringer ingelheim north ryde athens thai ltd bangkok boehringer ingelheim nz ltd auckland brazil p india turkey boehringer ingelheim brasil boehringer ingelheim portugal boehringer ingelheim ilac quimica e farmaceutica ltda india private ltd mumbai ticaret istanbul paulo boehringer ingelheim lda lisbon solana agro pecuaria ltda unilfarma lda lisbon indonesia p united kingdom arapongas pt boehringer ingelheim boehringer ingelheim ltd singapore indonesia jakarta bracknell canada boehringer ingelheim boehringer ingelheim singapore pte ltd singapore ireland usa p r canada ltd burlington boehringer ingelheim boehringer ingelheim corp south africa ireland limited dublin ridgefield connecticut chile boehringer ingelheim pty ltd boehringer ingelheim boehringer ingelheim ltda randburg pharmaceuticals inc italy p r santiago de chile ingelheim pharmaceutical pty ridgefield connecticut boehringer ingelheim ltd randburg boehringer ingelheim italia spa reggello usa corporation china p bidachem spa ridgefield connecticut south korea boehringer ingelheim shanghai fornovo giovanni boehringer ingelheim pharmaceuticals co ltd shanghai boehringer ingelheim korea ltd vetmedica inc boehringer ingelheim china seoul st joseph missouri japan p r investment co ltd shanghai boehringer ingelheim boehringer ingelheim vetmedica nippon boehringer ingelheim spain p fremont inc china co ltd shanghai co ltd tokyo fremont california boehringer ingelheim animal health boehringer ingelheim boehringer ingelheim operations china co ltd taizhou vetmedica japan co ltd espaa sa barcelona tokyo boehringer ingelheim sa barcelona boehringer ingelheim colombia p seiyaku co ltd yamagata europharma sa barcelona boehringer ingelheim sa boehringer ingelheim laboratorio fher sa barcelona bogot japan inc tokyo sweden denmark p mexico p r boehringer ingelheim ab stockholm boehringer ingelheim boehringer ingelheim danmark copenhagen promeco sa de cv switzerland mexico city boehringer ingelheim vetmedica boehringer ingelheim ecuador sa de cv guadalajara schweiz gmbh basel boehringer ingelheim del ecuador cia ltda quito consolidate financial statement consolidate balance sheet boehringer ingelheim consolidate profit loss statement c h boehringer sohn ag co kg ingelheim consolidate balance sheet asset millions eur note intangible asset tangible asset financial asset fix asset inventory account receivable asset security cash cash equivalent current asset prepaid expense defer taxis exceed plan asset total asset liability equity millions eur note shareholder capital group reserve balance sheet currency conversion difference equity attributable parent company noncontrolle interest group equity difference capital consolidation provision account payable loan liability defer charge defer taxis total liability equity explanation relevant section note consolidated financial statement product portfolio c h boehringer sohn ag co kg ingelheim consolidated profit loss statement million eur note net sale change finish good work process work capitalise operating income total revenue cost material personnel expense amortisation intangible asset depreciation tangible asset operating expense operate income financial income hold income income taxis income taxis income taxis net lossincome noncontrolle interest group lossprofit explanation relevant section note consolidated financial statement legal requirement disclosure shareholder personal taxis arise consolidated business activity tax expense allow taxis show withdrawal group reserve consolidate financial statement cash flow statement boehringer ingelheim tatement change group equity c h boehringer sohn ag co kg ingelheim cash flow statement million eur income taxis include thirdparty share amortisation intangible asset depreciation tangible asset change provision pension change provision noncash income expense gainloss disposal fix asset change inventory change account receivable asset relate investing financing activity change trade account payable liability relate investing financing activity interest incomeinterest expense net income investment incomeexpense extraordinary magnitude significance income tax cash receipt extraordinary magnitude significance income taxis pay cash flow operating activity investment intangible asset investment tangible asset investment noncurrent financial asset investment consolidated company proceed disposal intangible asset proceed disposal tangible asset proceed disposal noncurrent financial asset cash receipt extraordinary magnitude significance interest receive income dividend income taxis pay sale business cash flow investing activity product portfolio c h boehringer sohn ag co kg ingelheim cash flow statement million eur cash receipt grant interest pay cash payment owner parent entity cash repayment loan cash flow financing activity change liquid fund cash relevant transaction change liquid fund change consolidated company change liquid fund exchange rate movement financial fund financial fund excl fixedasset security liquid fund security fix current asset source fund use fund statement change group equity balance sheet equity attri currency butable non shareholders group conversion parent control millions eur capital reserve difference company interest group equity balance withdrawal net income change currency effect balance withdrawal net loss change consolidate company currency effect balance shareholder capital consist equity c h boehringer sohn ag co kg c h boehringer sohn grundstcksverwaltung gmbh co kg shareholders capital consist limited partner capital contribution shareholder personal taxis arise consolidated business activity show withdrawal group reserve december negative capital account limited partner eur million previous year eur million show net item group reserve liability limited partner reinstate eur consolidated financial statement note boehringer ingelheim c h boehringer sohn ag co kg ingelheim note consolidated financial statement principle method general principle consolidate financial statement boehringer ingelheim financial year prepare accordance section german commercial code hgb line legal requirement prepare consolidated financial statement section et seq hgb accordance section hgb consolidated financial statement consist consolidated balance sheet consolidated profit loss statement note consolidated financial statement cash flow statement statement change equity consolidated financial statement prepare euro accordance section conjunction section hgb improve clarity transparency consolidated financial statement individual item consolidate balance sheet consolidated profit loss statement combine item present explain separately note additional disclosure require individual item find note registry information parent company register c h boehringer sohn ag co kg headquarters ingelheim commercial register mainz district court number hra information company include consolidation parent company boehringer ingelheim group c h boehringer sohn ag co kg ingelheim boehringer ag ingelheim sole personally liable manage shareholder company c h boehringer sohn ag co kg c h boehringer sohn grundstcksverwaltung gmbh co kg general partner control c h boehringer sohn ag co kg boehringer ingelheim group consist total affiliated company germany abroad addition c h boehringer sohn ag co kg c h boehringer sohn grundstcksverwaltung gmbh co kg company c h boehringer sohn ag co kg directly indirectly hold majority voting right include consolidated financial statement consoli dation rule product portfolio accordance section hgb company include consolidation reporting year individually collectively insignificant group net asset financial earning position total sale equity net income year company include consolidation account aggregated group financial statement total affiliate company ongoing restriction control term article association company consolidate accordance section hgb total number affiliate company increase compare previous year company acquire exchange business area boehringer ingelheim sanofi complete january company pharmaton ssp co ltd sell exchange business area boehringer ingelheim sanofi seven company found company lose separate legal identity merger boehringer ingelheim animal health gmbh merial gmbh acquire exchange business area boehringer ingel heim sanofi unconsolidated affiliate company liquidate follow subsidiary exempt report disclosure obligation section hgb boehringer ingelheim gmbh ingelheim boehringer ingelheim europe gmbh ingelheim boehringer ingelheim secura versicherungsvermittlung gmbh ingelheim boehringer ingelheim grundstcksgesellschaft mbh ingelheim boehringer ingelheim finanzierung gmbh ingelheim boehringer ingelheim rd beteiligung gmbh ingelheim boehringer ingelheim venture fund gmbh ingelheim boehringer ingelheim invest gmbh ingelheim follow subsidiary company exempt duty prepare disclose annual financial statement management report accordance section b hgb c h boehringer sohn ag co kg ingelheim c h boehringer sohn grundstcksverwaltung gmbh co kg ingelheim boehringer ingelheim pharma gmbh co kg ingelheim c h boehringer sohn selbstmedikation gmbh co kg biberach boehringer ingelheim veterinary research center gmbh co kg hanover joint venture acquire exchange business area boehringer ingelheim sanofi include consolidated statement proportionate method equity method material consolidated financial statement note boehringer ingelheim accordance section hgb associated company include equity method lack significance consolidation method inventory fix asset receivables liability income expense item transaction company include consolidation eliminate debt consolidation procedure accordance section hgb procedure eliminate intercompany profit accordance section hgb income expense consolidation procedure accordance section hgb revaluation method apply include subsidiary company consolidation time accordance section hgb company include consolidation time date company subsidiary carrying share hold parent company offset correspond equity subsidiary equity carry fair value asset liability prepay expense defer income special reserve include consolidated financial statement time consolidation remain positive balance record goodwill remain negative balance record difference capital consolidation currency translation asset liability result foreign currency transaction translate average spot exchange rate balance sheet date realisation principle section conjunction section halfsentence hgb historical cost convention section conjunction section sentence hgb apply item remain term year consolidated financial statement financial statement foreign subsidiary domicile state outside eurozone denominate foreign currency convert euro accordance section hgb modify closing date rate method modify closing date rate method asset liability item annual financial statement prepare foreign currency translate euro average spot exchange rate balance sheet date exception equity translate historical rate item include profit loss statement translate euro average rate result translation difference report consolidated equity reserve balance sheet currency conversion difference annual financial statement country hyperinflation significant foreign currency item translate prior year exchange rate temporal method improve true fair view group net asset financial earning position product portfolio exchange rate group important currency change follow report year basis eur closing rate average annual rate dollar japanese yen pound sterle chinese renminbi accounting policy fix asset acquire intangible asset tangible fix asset carry cost schedule straightline amortisation depreciation determine consideration technical economic circumstance base follow useful life intangible asset year building year technical equipment machinery year equipment operate office equipment year straightline depreciation amortisation consolidated financial statement additional writedown record reflect impairment value asset consider permanently impair production cost include material labour manufacturing cost appropriate portion material labour overhead depreciation fix asset extent cause production capitalise intangible asset finite useful life financial asset primarily include shareholder right security loan carry low cost fair market value impair consolidated financial statement note boehringer ingelheim c urrent assets prepaid expense defer charge exceed plan asset inventory carry low cost fair market value raw material consumable supply capitalise low average acquisition price fair market value balance sheet date finish good work progress measure production cost basis individual calculation take account directly attributable cost material direct labour cost special direct cost appropriate share production material overhead cost depreciation good resale value lower purchase cost fair market value identifiable risk inventory asset arise aboveaverage storage period diminish marketability low replacement cost take account record appropriate valuation adjustment inventory value lossfree e deduction expect sale price reflect cost incur receivables asset recognise cost allowance specific risk general credit risk lowinter noninterestbeare receivables term year discount security classify current asset include security recognise low cost quotedmarket price report date cash cash equivalent consist cash balance bank cheque recognise low cost fair market value prepay expense record accordance section hgb include expense pay advance respect define period time balance sheet date defer charge record accordance section hgb include proceed represent income respect define period time balance sheet date fair market value plan asset correspond present value pension obligation offset accord german gaap exceeding plan asset capitalise separately product portfolio difference capital consolidation difference capital consolidation report december previous year result exclusively acquisition company original difference amount eur mil lion difference amortise estimate period year remain balance difference amount eur million december reduction release eur million current period effect change exchange rate addition increase difference capital consolidation report december result exchange business area boehringer ingelheim consumer health care business chc sanofis animal health business merial complete january accordance accounting policy select boehringer ingelheim application exchange principle book value method acquisition cost shareholding merial company acquire sanofi equal cash compensation include assume obligation eur million plus carry chc business transfer exchange eur million proportional equity share merial company january eur million correspond fair value acquire asset liability take noncontrolle interest account resulted difference capital consolidation eur million amortisation period difference transaction estimate year remain carry difference december release eur million current financial year amount eur million release financial year influence oneoff effect primarily consequence tax reform usa income release difference arise capital consolidation include operate income release correspond amortisation asset acquire company identify purchase price allocation previously recognise company balance sheet hide den asset group reserve group reserve include retain earning consolidate subsidiary prior current year consolidation entry affect earning provision tax provision provision include uncertain liability expect loss executory contract carry require settle obligation base reasonable prudent commercial judgement e include future cost price increase provision remain maturity year discount matchedterm average market interest rate case pension provision interest rate result year case provision seven year accordance rckstellungsabzinsungsverordnung german regulation discount provision account payable loan account payable loan recognise settlement consolidate financial statement note boehringer ingelheim defer taxis calculate defer taxis arise tax loss carry forwards temporary quasipermanent difference carry amount asset liability prepay expense defer charge commercial balance sheet carrying amount tax purpose amount result tax benefit expense time difference reverse measure tax rate specific respective consolidated company defer tax balance discount difference consolidation measure accordance section hgb measure company specific tax rate applicable time expect reversal difference defer tax asset loss carryforward take account likely year defer tax asset liability report offset explanation comparability previous year figure result exchange consumer health care business chc sanofis animal health business merial significant change composition consolidate company financial year order provide well comparability consecutive consolidated financial statement significant balance sheet profit loss statement item adjust consumer health care business discontinue newly acquire animal health business balance sheet million eur incl merial thereof merial excl merial incl chc thereof chc excl chc fix asset current asset liability explanation decrease adjust current asset report december refer chapter note profit loss statement thereof millions eur incl merial merial tdsa chc excl merial incl chc thereof chc excl chc net sale number earning chc business unit base management report c h boehringer sohn ag co kg diverge actual transaction amount difference significant product portfolio order derive comparable figure net sale adjust newly acquire animal health business sale govern transitional service production agreement transaction sanofi tdsatsa information performance adjust net sale refer statement report eco nomic position management report operating expense income previous year subject significant positive negative extraordinary onetime effect mean comparative presentation similar manner net sale result well comparability regard extraordinary onetime effect refer chapter note change personnel expense correspond change number employee overall employee transfer sanofi transfer group disposal consumer health care business cost material increase newly aquire animal health business subject exceptional effect mean comparative presentation similar manner net sale result well comparability regard exceptional effect refer chapter note addition animal health business capital intensive chc business increase depreciation amortisation tangible intangible fix asset primarily amortisation intangible asset aquire transaction consolidated financial statement note boehringer ingelheim note consolidated balance sheet intangible asset acquire concession advance millions eur similar right goodwill payment total procurementmanufacture cost balance currency conversion difference change consolidate company addition disposal reclassification balance currency conversion difference change consolidate company addition disposal reclassification balance accumulate depreciation balance currency conversion difference change consolidate company addition writeup disposals reclassification balance currency conversion difference change consolidate company addition writeup disposal reclassification balance book value book value product portfolio tangible asset advance technical facility payment land facility operating construction million eur building machine equipment progress total procurementmanufacture cost balance currency conversion difference change consolidate company addition disposal reclassification balance currency conversion difference change consolidate company addition disposal reclassification balance accumulate depreciation balance currency conversion difference change consolidate company addition writeup disposal reclassification balance currency conversion difference change consolidate company addition writeup disposal reclassification balance book value book value consolidate financial statement note boehringer ingelheim financial asset investment loan investment affiliate affiliate relate advance investment million eur company company company payment security loan total procurementmanufacture cost balance currency conversion difference change consolidate company addition disposal reclassification balance currency conversion difference change consolidate company addition disposal reclassification balance accumulate amortisation balance currency conversion difference change consolidate company addition writeup disposal reclassification balance currency conversion difference change consolidate company addition writeup disposal reclassification balance book value book value previous year loan item include loan shareholder product portfolio inventory million eur raw material supply unfinished good finish good good resale advance payment supplier account receivable asset residual residual term term millions eur year year trade account receivable receivables affiliate company receivables related company asset asset item include receivables shareholder eur million previous year eur million receivable affiliate company exclusively consist receivables loan receivables related company primarily consist trade account receivable provision million eur provision pension similar obligation tax provision provision consolidated financial statement note boehringer ingelheim provision pension similar obligation provision pension similar obligation determine basis actuarial calculation project unit credit method take account future adjustment salarie pension addition local biometric datum eg germany mortality table g publish prof dr klaus heubeck pension obligation significant country calculate basis follow actuarial parameter december germany usa japan discount rate salary increase pension increase discount rate determine reference average market rate year maturity accordance german regulation discount provision march interest rate discount significant foreign pension obligation usa japan determine comparable parameter line german regulation discount provision march difference calculate accordance section hgb amount eur million plan asset intend solely cover pension similar obligation unavailable creditor plan asset define section sentence hgb measure fair market value essentially derive stock market price offset underlie pension similar obligation fair market value plan asset balance sheet date eur million relate pension obligation similar obligation eur million gain loss plan asset interest expense relate pension similar obligation offset accordance section sentence hgb total eur million earning plan asset eur million interest expense relate pension similar obligation include financial result tax provision tax provision include provision double taxation risk result follow imple mentation action plan organisation economic cooperation development oecd international initiative know action plan base erosion profit shift bep provision provision mainly include provision discount guarantee provision litigation legal claim compensation damage provision outstanding invoice provision assume risk course business exchange sanofi personnelrelate provision product portfolio account payable loan residual term residual term greater great million eur year year year year bank loan account payable trade account payable advance payment receive account payable affiliate company account payable relate company liabilitie taxis eur million social security liability eur million previous year liability secure mortgage similar collateral right balance sheet date end year liability shareholder eur million previous year eur million present liability item account payable affiliate company include loan amount eur million previous year eur million trade account payable amount eur million previous year eur million consolidated financial statement note boehringer ingelheim note consolidated profit loss statement structure consolidated profit loss statement base total cost format taxis include operating expense net sale business business segment millions eur human pharmaceutical animal health biopharmaceutical industrial customer sale dicontinue operation geographic region millions eur europe germany americas usa asiaaustraliaafrica japan operating income operating income financial year include exceptional onetime income amount eur million particular result sale business usa order adjust animal health product portfolio antitrust reason release provision operating income include income currency translation eur million previous year eur million cost material million eur cost raw material supply good resale expenditure service product portfolio cost material affect impact sale inventory newly acquire merial company inventory value market value january eur million personnel expense million eur wage salarie social benefit retirement benefits retirement benefit interest effect measurement provision pension similar obligation show separate item financial income average headcount production administration marketing sale research development apprentice amortisation intangible asset depreciation tangible asset amortisation intangible asset depreciation tangible fix asset include extraordinary writedown eur million previous year eur million operating expense operating expense include expense currency translation eur million previous year eur million total operating expense affect impact exceptional onetime expense amount eur million connection exchange business area sanofi addition item include operating expense mainly charge record provision legal risk restructure thirdparty service research development medicine marketing purpose administrative expense fee contribution commission rent freight expense repair carry party consolidate financial statement note boehringer ingelheim financial income millions eur interest expense relate pension similar obligation provision interest expense similar expenditure interest expense similar expenditure amortisation loss disposal financial asset shortterm investment income investment security longterm loan interest income similar proceed hold income million eur writeoff financial asset income relate company disposal related company income taxis million eur current income taxis defer taxis income tax expense affect significant extraordinary effect tax expense current period include tax expense arise disposal chc business approximately eur billion usa tax reform approve december tax cut job act require reassessment defer tax asset liabilitie corporate income tax rate enact law balance sheet date future financial year result significant increase tax expense eur million current income taxis primarily include corporation trade tax expense company include consolidation total balance defer tax asset balance sheet amount eur million previous year eur million defer tax asset primarily arise difference carry amount provision pension obligation discount tax goodwill fix asset inventory defer tax liability eur million previous year eur million record primarily relate difference carry amount intangible asset tangible asset inventory provision product portfolio group loss group loss positively influence priorperiod operate income primarily reversal provision eur million previous year eur million negatively influence priorperiod operating expense eur million previous year eur million note cash flow statement cash flow statement show change cash cash equivalent cash longterm security investment classify current asset sell time boehringer ingelheim group result cash outflow report year accordance german accounting standard cash flow statement dr cash flow statement break accord cash flow operating activity cash flow invest financing activity change balance sheet item affiliate company include translate average rate year balance sheet cash cash equivalent carry closing rate effect exchange rate change cash cash equivalent show separately financial fund include financial asset remain maturity excess month date acquisition financial asset convert cash shortterm financial fund december comprise follow item million eur cash cash equivalent security financial asset financial fund include eur million restrict fund balance sheet date financial year interest eur million previous year eur million receive interest eur million previous year eur million taxis eur million previous year eur million pay consolidated financial statement note boehringer ingelheim disclosure contingent liability millions eur liability guarantee warranty grant security thirdparty liability risk utilisation contingent liability assess low account good net asset financial position earning financial commitment offbalance sheet transaction millions eur rental leasing obligation purchase commitment obligation rental lease agreement eur million previous year eur million eur million previous year eur million relate longterm rental agreement sub sidiarie include consolidation purpose lease agreement low capital commitment compare buy property absence resale risk risk arise term lease possible continue utilise property fully indication time financial commitment include future expense followup investment investment initiate future major repair balance sheet date purchase commitment include future cash flow effect investment total eur million previous year eur million derivative financial instrument valuation unit extensive international structure boehringer ingelheim group highly dependent devel opment world currency interest rate hedge risk particularly emerge good service finance currency forwards option generally currency risk interest rate swap option interest rate risk use derivative financial instrument organisational process set internal guideline strict separation trading processing documentation control product portfolio risk position regularly track analysed measure special groupwide financial report position enter periodically reevaluate monitor fair value derivative financial instrument calculate generally accept market valuation method currency forward base present value method take account market datum balance sheet date provision eur million recognise currency forward include hedge accounting negative fair value currency balance sheet date line imparity principle positive fair value currency recognise balance sheet date derivative financial instrument include hedge accounting valuation group follow nominal value fair value millions eur foreign exchange forward contract extent requirement hedge account foreign currency forward exchange contract highly probable forecast transaction accordance section hgb meet foreign currency forward exchange contract recognise balance sheet line net hedge presenta tion method follow accounting policy apply recognition valuation group accordance ection hgb economic hedge account financial statement use valuation group valuation group recognise foreign currency base net highly probable forecast transaction currency forwards match forecast net cash flow term maturity nominal foreign currency macro hedge highly probable forecast transaction income outgoing payment plan sale purchase derive company plan expost analysis planning show plan transaction highly probable oppose change value hedge item hedge instrument fully offset critical term maturity nominal foreign currency match effective hedge assume prospectively retrospectively critical term match method exclusively measure prospective retrospective effectiveness hedge excess amount hedging transaction include valuation group consolidate financial statement note boehringer ingelheim december hedge highly probable forecast net cash flow recognise follow january december net cash flow million eur fx forward contract millions eur nominal value nominal value fair value usd usd usd jpy jpy jpy aud aud aud mxn mxn mxn cad cad cad gbp gbp gbp january december net cash flow million eur fx forward contract millions eur nominal value nominal value fair value usd usd usd jpy jpy jpy aud aud aud mxn mxn mxn cad cad cad gbp gbp gbp january december net cash flow million eur fx forward contract millions eur nominal value nominal value fair value usd usd usd jpy jpy jpy january february net cash flow million eur fx forward contract millions eur nominal value nominal value fair value usd usd usd jpy jpy jpy year hedge accounting valuation group long short posi tion derivative offset nominal value eur million japanese yen eur million dollar product portfolio furthermore december valuation group foreign currency receivable recognise follow receivables millions eur forward exchange contract millions eur nominal value nominal value fair value rub rub rub pln pln pln hedge foreign currency risk correlate relative change exchange rate planning date realisation date forecast transaction currency appreciate depreciate euro foreign currency risk plus minus eur million hedge research development expense million eur research development expense noncapitalise research development expense include item cost associate clinical study report postbalance sheet date event end financial year aware event material significance group lead reappraisal net asset financial position earning total auditor fee total fee charge group auditor financial year amount eur million eur million relate audits financial statement eur million assurance service eur million tax advisory service eur million service independent auditor report boehringer ingelheim independent auditor report c h boehringer sohn ag co kg ingelheim qualified audit opinion consolidated financial statement audit opinion group management report audit consolidated financial statement c h boehringer ingelheim sohn ag co kg ingelheim subsidiary group comprise consolidated balance sheet december consolidated income statement consolidate statement change equity consolidated cash flow statement financial year january december note consolidated financial statement include recognition measurement policy present addition audit group management report ch boehringer ingel heim sohn ag co kg financial year january december opinion basis knowledge obtain audit effect matter describe section basis qualified audit opinion consolidated financial statement audit opinion group management report accompany consolidated financial statement comply material respect requirement german commercial law consolidated financial statement true fair view asset liability financial position group december financial performance financial year january december compliance german legally require accounting principle accompany group management report provide appropriate view group position material respect group management report consistent consolidated financial statement complie german legal requirement appropriately present oppor tunitie risk future development pursuant article ab paragraph satz sentence hgb handelsgesetzbuch german commercial code declare qualification audit opinion consolidated financial statement mention audit lead reservation relate legal compliance consolidated financial statement group management report basis qualified audit opinion consolidated financial statement audit opinion group management report contrary abs nr number buchstaben letter b hgb total remuneration grant member member board manage director pension provision recognize recognize member board manage director disclose note consolidated financial statement product portfolio conduct audit consolidated financial statement group management report accordance hgb compliance german generally accept standard financial statement audits promulgate institut der wirtschaftsprfer institute public auditor germany idw responsibility requirement principle describe auditor responsibility audit consolidated financial statement group management report section auditor report independent group entity accordance requirement german commercial professional law fulfil german pro fessional responsibility accordance requirement believe audit evidence obtain sufficient appropriate provide basis qualified audit opinion consolidated financial statement audit opinion group management report information executive director responsible information information comprise annual report exclude crossreference external information exception audit consolidated financial statement audit group management report auditor report audit opinion consolidate financial statement group management report cover information consequently express audit opinion form assurance conclusion thereon connection audit responsibility read information consider information materially inconsistent consolidated financial statement group management report knowledge obtain audit appears materially misstate responsibility executive director consolidate financial statement group management report executive director responsible preparation consolidated financial statement comply material respect requirement german commercial law consoli date financial statement true fair view asset liability financial position financial performance group compliance german legally require accounting principle addi tion executive director responsible internal control accordance german legally require accounting principle determine necessary enable preparation consolidated financial statement free material misstatement fraud error independent auditor report boehringer ingelheim prepare consolidated financial statement executive director responsible assess group ability continue go concern responsibility disclose applicable matter relate go concern addition responsible financial reporting base go concern basis accounting provide actual legal circumstance conflict therewith furthermore executive director responsible preparation group management report provide appropriate view group position material respect consistent consolidated financial statement complie german legal requirement appropriately present opportunity risk future development addition executive director responsible arrangement measure system consider necessary enable preparation group management report accordance applicable german legal requirement able provide sufficient appropriate evidence assertion group management report auditor responsibility audit consolidated financial statement group management report objective obtain reasonable assurance consolidated financial statement free material misstatement fraud error group management report provide appropriate view group position material respect consistent consolidated financial statement knowledge obtain audit complie german legal requirement appropriately present opportunity risk future development issue auditor report include audit opinion consolidate financial statement group management report reasonable assurance high level assurance guarantee audit conduct accordance hgb compliance german generally accept standard financial statement audits promulgate institut der wirtschaftsprfer idw detect material misstatement misstatement arise fraud error consider material individually aggregate reasonably expect influence economic decision user take basis consolidated financial statement group management report product portfolio exercise professional judgment maintain professional skepticism audit identify assess risk material misstatement consolidated financial statement group management report fraud error design perform audit procedure responsive risk obtain audit evidence sufficient appropriate provide basis audit opinion risk detect material misstatement result fraud high result error fraud involve collusion forgery intentional omission misrepresentation override internal control obtain understand internal control relevant audit consolidate financial statement arrangement measure system relevant audit group management report order design audit procedure appropriate circumstance purpose express audit opinion effectiveness system evaluate appropriateness accounting policy executive director reasona bleness estimate executive director relate disclosure conclude appropriateness executive director use go concern basis accounting base audit evidence obtain material uncertainty exist relate event condition cast significant doubt group ability continue go concern conclude material uncertainty exist require draw attention auditor report relate disclosure consolidate financial statement group management report disclosure inadequate modify respective audit opinion conclusion base audit evidence obtain date auditor report future event condi tion cause group cease able continue go concern evaluate overall presentation structure content consolidated financial statement include disclosure consolidated financial statement present underlying transaction event manner consolidated financial statement true fair view asset liability financial position financial performance group compliance german legally require accounting principle obtain sufficient appropriate audit evidence financial information entity business activity group express audit opinion consolidate financial statement group management report responsible direction supervision performance group audit remain solely responsible audit opinion evaluate consistency group management report consolidate financial statement conformity german law view group position provide independent auditor report boehringer ingelheim perform audit procedure prospective information present executive director group management report basis sufficient appropriate audit evidence evaluate particular significant assumption executive director basis prospective information evaluate proper derivation prospective information assumption express separate audit opinion prospective information assumption basis substantial unavoidable risk future event differ materially prospective information communicate charge governance matter plan scope time audit significant audit finding include significant deficiency internal control identify audit frankfurt main march pricewaterhousecooper gmbh wirtschaftsprfungsgesellschaft dr ulrich strk michael conrad wirtschaftsprfer wirtschaftsprfer german public auditor german public auditor product portfolio p r u c p r f l e l e c n human pharmaceutical animal health product portfolio human pharmaceutical boehringer ingelheim respiratory disease respiratory disease common chronic obstructive bronchial asthma pulmonary disease copd bronchial asthma bronchial asthma chronic inflammatory disorder prevalent chronic disease frequent airways inflammation accompany airway cause morbidity premature death worldwide hyperresponsiveness lead narrow airways recurrent episode wheeze breathless idiopathic pulmonary fibrosis ipf rare disease ness cough symptom occur particularly severely debilitate ultimately lethal night early hour morning know asthma trigger genetic envi copd ronmental factor eg allergen viral infection copd chronic disease lung cause cough unlike copd asthma occur early childhood e excessive mucus production dyspnea ulti present adolescent adult asthma mately destroy lung tissue alveolus gas underestimate easytomanage condition exchange affect lead limitation patient asthma airflow cause shortness breath respira experience symptom receive maintenance ther tory symptom airflow limitation partially apy put increase risk potentially reversible usually worsen time lead disa lifethreatening asthma exacerbation addition bility ultimately death symptom excess patient adjust daily life accommodate cough breathlessness main reason copd condition avoid physical exertion daytoday stressful patient lung emphysema chronic activity negative impact quality life bronchitis main manifestation copd copd cause continuous damage lung result ing inhale pollutant primarily cigarette smoke factor need consider includ ing indoor outdoor air pollution course copd disease occur second half human life characterise accelerate loss lung function compare normal age occasional sudden worsen symptom function refer acute exacerbation lead downward spiral worsen symptom fur ther inactivity indication brand name active ingredient chronic obstructive spiriva tiotropium bromide maintenance treatment patient pulmonary disease copd spiriva handihaler copd include chronic bronchitis spiriva respimat emphysema maintenance treatment associate dyspnoea prevention exacerbation bronchial asthma spiriva respimat tiotropium bromide addon maintenance treatment adult patient asthma currently treat maintenance combination inhale corticosteroid spiriva respimat approve use asthma eu japan usa country label vary country refer local product information chronic obstructive spiolto respimat tiotropium bromide maintenance treatment airflow pulmonary disease copd stiolto respimat olodaterol obstruction patient chronic inspiolto respimat hydrochloride obstructive pulmonary disease copd chronic obstructive striverdi respimat olodaterol maintenance treatment patient pulmonary disease copd hydrochloride chronic obstructive pulmonary disease copd reversible bronchospasm combivent respimat ipratropium bromide combination shortacting associate obstructive salbutamol sulphate anticholinergic betaadrenergic airway disease management reversible broncho spasm associate obstructive airway disease patient require bronchodilator chronic obstructive atrovent ipratropium bromide prevention treatment shortness pulmonary disease copd breath patients chronic chronic bronchitis obstructive pulmonary disease copd bronchial asthma mild moderate bronchial asthma adulthood childhood supple ment betaagonist case acute asthma chronic obstructive airway berodual ipratropium bromide fenoterol prevention treatment symptom disorder bronchodual hydrobromide chronic obstructive airway disorder duovent reversible airflow limitation bronchial asthma especially chronic bronchitis emphysema product portfolio human pharmaceutical boehringer ingelheim respiratory disease continue idiopathic pulmonary fibrosis ipf acute ipf exacerbation define rapid deterioration ipf chronic progressive lung disease associate symptom lung function day week markedly reduce life span affect event occur point course disease people worldwide ipf characterise presentation associate high mor progressive scar lung tissue loss lung tality patient ipf risk acute ipf exacer function time development scar tissue call bation fibrosis time tissue thicken stiffen scar lung lose ability transfer oxygen blood stream vital organ oxygen result individual ipf experience shortness breath rest difficulty cope demand everyday life limited physical capacity indication brand name active ingredient bronchial asthma berotec fenoterol hydrobromide symptomatic treatment acute asthma attack prophylaxis exerciseinduce asthma bronchiale symptomatic treatment allergic nonallergic asthma bronchiale condition reversible airway narrow eg chronic obstructive b ronchitis bronchial asthma alesion epinastine hydrochloride prophylactic treatment patient allergic rhinitis flurinol bronchial asthma prophylaxis symp tomatic treatment allergic rhinitis idiopathic pulmonary fibrosis ofev nintedanib treatment patient idiopathic ipf pulmonary fibrosis ipf product portfolio human pharmaceutical boehringer ingelheim cardiovascular metabolic disease cardiovascular cv disease leading cause death prevention treatment venous country increase prevalence thromboembolism currently responsible nearly death venous thromboembolism vte umbrella term worldwide key risk factor develop cardio encompasse deep vein thrombosis dvt pulmonary vascular disease presence diabete people embolism pe dvt process occur diabete time likely develop thrombus blood clot form deep vein commonly cardiovascular disease people diabetes calf leg partially completely blocks result life expectancy year shorter flow blood thrombus grow portion proper control diabete treatable risk factor break away main clot travel circulatory vital prevention cardiovascular event system lung lodge blood clot artery lung call pe vte disor stroke der potentially fatal consequence stroke rapidly develop loss brain function cause reduced blood flow affect brain tis patient undergo orthopaedic surgery considerable sue ischaemia lack blood supply risk develop dvt chronic venous insufficiency cause thrombosis embolism bleed andor pulmonary hypertension develop long result affect area brain unable term prevent vte event consequence function damage quickly permanent orthopaedic surgery patient receive kind untreated stroke acute event require emergency thromboprophylaxis patient suffer diagnosis intervention worldwide stroke vte require anticoagulant treatment secondary leading cause death longterm disability prevention recurrent thromboembolic event symptom transient ischaemic attack tia similar stroke minute hour reverse anticoagulation usually result permanent neurological damage anticoagulant offer important benefit patient risk tia precede stroke emergency medical care thromboembolic event rare subsequent preventive treatment necessary situation rapid reversal anticoagu lation medically necessary eg patient take atrial fibrillation anticoagulant involve severe car accident atrial fibrillation af common sustained need emergency surgery heart rhythm condition affect approximately total population adult develop arrhythmia lifetime patient af high risk develop blood clot upper leave heart chamber cause disable stroke clot break loose travel brain af lead fivefold increase risk stroke result ing million patient worldwide suffer afrelate stroke year risk stroke reduce effective chronic anticoagulation indication brand name active ingredient stroke prevention atrial pradaxa dabigatran etexilate prevention stroke blood clot fibrillation pradaxar patient abnormal heart rhythm primary prevention venous prazaxa atrial fibrillation thromboembolic event primary prevention venous thrombo orthopaedic surgery embolic event vte adult treatment secondary elective total hip knee replacement prevention venous throm surgery boembolic event treatment deep vein thrombosis dvt pulmonary embolism pe secondary prevention recurrent dvt pe adult specific reversal pradaxa praxbind idarucizumab praxbind specific reversal agent dabigatran etexilate dabigatran indicate dult patient treat pradaxa dabigatran etexilate rapid reversal anticoaculant effect require emergency surgeryurgent procedure lifethreatene uncontrolled bleed hypertension micardis telmisartan treatment hypertension cardiovascular morbidity micardisplus telmisartan hydrochlorothiazide reduction risk myocardial mortality prevention micardi plus infarction heart attack stroke death cardiovascular cv cause micardis hct patient year age old high comicardi risk develop major cv event unable ace inhibitor usa reduction cardiovascular mor bidity patient manifest athero thrombotic cardiovascular disease history coronary heart disease stroke peripheral arterial disease patient type diabetes mellitus docu mente target organ damage eu h ypertension twynsta telmisartan amlodipine treatment hypertension micamlo antihypertensive agent initial micardis amlo therapy patient likely need multi ple antihypertensive agent achieve micardis duo blood pressure goal usa addon therapy adult patient adequately control blood pre sure amlodipine replacement therapy adult patient receive tel misartan amlodipine separate tablet eu product portfolio human pharmaceuticals boehringer ingelheim cardiovascular metabolic disease continue hypertension cardiovascular disease hypertension refer high blood pressure chronic disease blood pressure chronically elevated hypertension major risk factor stroke heart attack heart failure chronic renal failure primary goal antihypertensive treatment prevent cardiovascular event reduce cardiovascular mortality acute myocardial infarction acute myocardial infarction heart attack event occur thrombus clot suddenly pre vent blood flow area heart muscle blood flow restore quickly affect section heart muscle permanently damage heart attack leading cause death develop country indication brand name active ingredient acute ischaemic stroke actilyse alteplase fibrinolytic treatment acute ischae acute myocardial infarction actilyse cathflo mic stroke acute myocardial infarction acute massive pulmonary acute massive pulmonary embolism embolism fibrinolytic treatment occluded catheter clearance catheter thrombotic occlusion secondary prevention aggrenox dipyridamole prevention stroke follow initial stroke transient ischaemic asasantin acetylsalicylic acid stroke transient ischaemic attack tia asasantin retard attack tia acute myocardial infarction metalyse tenecteplase fibrinolytic treatment acute myocar dial infarction hypertension catapresan clonidine treatment hypertension catapre clonidine hydrochloride catapressan cataprestts hypertension motens lacidipine treatment hypertension product portfolio human pharmaceuticals boehringer ingelheim cardiovascular metabolic disease continue diabete overall half death people type dia type diabetes chronic progressive condition associate bete cause concomitant cardiovascular disease elevate blood sugar level cause longterm indicate high unmet medical need complication treat addition cardiovascular disease complication approximately million death worldwide year diabete include link directly longterm effect diabete type diabete common form disease nephropathy culminate renal failure require account case develop world dialysis currently million people world live retinopathy potential loss vision diabetes represent enormous burden peripheral neuropathy risk develop foot health care system globally effective pre vention ulcer potentially require foot leg amputation management strategy estimate num autonomic neuropathy cause gastrointestinal ber case reach million genitourinary cardiovascular symptom sexual dysfunction addition type diabete major risk factor cardio vascular disease life expectancy people type dia bete high cardiovascular risk decrease average year indication brand name active ingredient type diabete mellitus trajenta linagliptin treatment type diabete mellitus tradjenta adjunct diet exercise trazenta improve glycaemic control adult monotherapy metformin trayenta tolerate contraindicated combination therapy type diabete mellitus jentadueto linagliptin metformin hydrochloride treatment type diabete mellitus trayenta duo adjunct diet exercise trajenta duo improve glycaemic control adult treatment metformin trajentamet lead sufficient control patient treat trajenta linagliptin metformin type diabete mellitus jardiance empagliflozin treatment adult type diabete jardianz mellitus adjunct diet exer cise improve glycaemic control reduce risk cardiovascular death adult type diabete mellitus establish cardiovascular disease usa indication december label vary country refer local product information type diabete mellitus synjardy empagliflozin treatment type diabete mellitus jardiance duo metformin adjunct diet exercise improve hydrochloride glycaemic control adult treat ment empagliflozin meet formin hydrochloride appropriate usa indication december label vary country refer local product information type diabete mellitus glyxambi empagliflozin linagliptin treatment type diabete mellitus adjunct diet exercise improve glycaemic control adult type diabetes mellitus empagli flozin linagliptin appropriate treatment usa indication march label vary country refer local product information iabete portfolio collaboration eli lilly company product portfolio human pharmaceutical boehringer ingelheim oncology cancer threat global health estimate unspecific disease year million new case cancer diagnose world appear late diagnosis advanced stage disease wide million people die cancer nearly result dismal prognosis global death world cancer factsheet lung cancer patient survive year follow common diagnose cancer type lung ing diagnosis cer nearly liver cancer colorectal cancer stomach cancer breast cancer lung cancer disease dif ferent subtype small cell lung cancer sclc lung cancer nonsmall cell lung cancer nsclc differ lung cancer refer malignant abnormal cell growth ent molecular genetic aberration mutation present inside lung tissue form cluster tumour tumour identify focus molecular common cancer estimate million new change specific respective subtype lung case year worldwide smoking primary cancer target therapy effective cause disease contribute nearly case treatment survival benefit recently incidence lung cancer time harmful normal cell nonsmoker increase lung cancer poor prog reduce effect nosis million death year represent nearly cancer death lung cancer symptom indication brand name active ingredient nonsmall cell lung cancer giotrif afatinib firstline treatment patient nsclc gilotrif metastatic nonsmall cell lung cancer nsclc tumour activate epidermal growth factor receptor egfr mutation treatment patient locally advanced metastatic nsclc squamous histology progress ing platinumbase chemo therapy nonsmall cell lung cancer vargatef nintedanib combination therapy docetaxel nsclc treatment adult patient locally advanced metastatic locally nonsmall cell lung cancer nsclc adenocarcinoma tumour histology firstline chemotherapy product portfolio human pharmaceuticals boehringer ingelheim disease central nervous system mental neurological disease depression depression sleep disorder primary symptom parkinson disease significantly impact patient result lack neurotransmitter dopamine family substantial burden society distinct area human brain parkinson disease restless leg syndrome rls parkinson disease pd degenerative disorder restless leg syndrome rls common neurological central nervous system patient usually notice motor disorder characterise uncontrollable urge symptom like hand tremor shake sign leg primarily occur evening night disease progress include shake hour usually accompany unpleasant arm leg head motor symptom time painful sensation leg disturb develop time include stiffness result sleep result daytime tiredness sleepiness loss facial expression gradual slow loss sensation feel deep leg describe motion freeze patient creep crawl ache suffer nonmotor symptom associate pd infectious disease hiv infectionaid acquire immune deficiency syndrome aid set symptom infection result damage human immune system cause human immu nodeficiency virus hiv untreated infection hiv progressively reduce effectiveness immune system leave individual susceptible opportunistic infection tumour baby infect mother risk get virus pregnancy childbirth breastfeed indication brand name active ingredient parkinson disease pd sifrol pramipexole symptomatic treatment idiopathic restless leg syndrome rls mirapex parkinson disease mirapexin monotherapy combination levodopa symptomatic treatment pexola idiopathic moderate severe restless leg syndrome sleep disorder lendormin brotizolam shortterm treatment disorder initiate maintain sleep insomnia require pharmacological intervention indication brand name active ingredient hivaid viramune nevirapine combination therapy hiv viramune xr infection country prevention mothertochild transmission hiv pregnant woman take antiretroviral therapy time labour prolong release tablet oncedaily dose combination therapy hivaids aptivus tipranavir indicate combination antiretroviral treatment hivinfecte patient coadministere mg ritona vir treatmentexperience infect hiv strain resistant protease inhibitor product portfolio animal health boehringer ingelheim livestock swine infectious respiratory disease infectious enteric disease ingelvac circoflex singledose piglet vaccine enterisol ileitis oral live vaccine control porcine circovirus disease pcvd ileitis globally prevalent enteric disease vaccine provide significant reduction mortality cause lawsonia intracellularis license acute phase pcvd improve growth rate improve weight gain reduce growth variability chronic phase disease ingelvac circoflex associated disease enterisol ileitis help protect minimal systemic adverse reaction reduce total antimicrobial use pork production injection site swelling gestation lactation ingelvac prrs product license active immunisation respiratory repro ductive form porcine reproductive respiratory syndrome prrs ingelvac mycoflex provide proven safety efficacy rapid onset longlaste immunity myco plasma hyopneumoniae hyo single dose ingelvac mycoflex contain impranflex adju vant allow fresh mix ingelvac c ircoflex form flexcombo indication brand name active ingredient infectious respiratory ingelvac circoflex recombinant vaccine active immunisation pig disease porcine circovirus age week porcine type pcv circovirus type reduce mortality clinical sign include weight loss lesion lymphoid tissue asso ciate porcine circovirus disease pcvd addition vaccination show reduce pcv nasal shed de viral load blood lymphoid tissue duration viraemia infectious respiratory ingelvac prrs mlv attenuate live vaccine prrs virus depend product disease ingelvac prrsflex eu type active immunisation pig reprocyc prrs eu type age porcine reproductive respiratory syndrome virus prrsv infectious respiratory ingelvac mycoflex inactivate vaccine active immunisation pig disease mycoplasma age week reduce lung hyopneumoniae lesion follow infection myco plasma hyopneumoniae infectious enteric disease enterisol ileitis attenuate live vaccine active immunisation pig lawsonia age week intestinal intracellularis lesion cause lawsonia intracellularis infection reduce growth variability loss weight gain associate disease product portfolio animal health boehringer ingelheim livestock cattle cattle business global leader antiparasitic brand ivomec longrange eprinex world renowne parasiticide treat protect graze animal harmful effect internal external parasite zactran treat cattle bacterial pneumonia sheep digital dermatitis infection vaccine pyramidpresponse ex pand e portfolio respiratory reproductive vaccine prevent disease affect livestock indication brand name active ingredient internal external ivomec ivermectin depend formulation product parasite cattle treatment nematode lice mite tick fly lungworm liver fluke internal external longrange eprinomectin longacting theraphase technology parasite cattle develop formulation eprinomectin allow single treatment day long break parasite life cycle effectively reduce parasite burden pasture longrange effective control internal external parasite cattle gastrointestinal roundworm lungworm grub mite internal external eprinex eprinomectin depend formulation product parasite ruminant treatment nematode lice mite tick fly lungworm cattle sheep bacterial cause respiratory zactran gamithromycin depend specie indication disease interdigital country registration product dermatitis footrot treatment metaphylaxis control key bacteria cause respira tory disease cattle mannheimia pasteurella histophilus mycoplasma key bacteria cause footrot disease sheep fusobacterium dichelobacter respiratory reproductive pyramid family multivalent vaccine combi pyramidpresponse family infectious disease cattle presponse nation include different modify vaccine provide broad coverage live virus bvd type ibr brsv pi bovine viral diarrhoea bvd type mannheimia haemolytica infectious bovine rhinotrache single dose contain metastim itis ibr parainfluenza pi adjuvant system enhance animal bovine respiratory syncytial virus response great protection brsv bacteria pasteurella canada multocida mannheimia haemolyt ica l canicola l grippotyphosa l hardjo l icterohaemmorrhagiae l pomona product portfolio animal health boehringer ingelheim livestock poultry volvac umbrella brand poultry vaccine range consist wide range live inactivate vaccine broiler layer vaccine provide protection bird viral bacterial disease like avian influenza infectious bronchitis newcastle disease infectious bursal disease egg drop syndrome avian coryza acquisition merial enlarge portfolio additional vaccine include leader respective segment indication brand name active ingredient viral bacterial volvac polyvalent attenuate live vaccination healthy chicken disease poultry inactivated vaccine disease cause include contain antigen antigen prevention vaccination avian common disease broiler chicken influenza newcastle disease responsible loss disease avian coryza egg egg production layer drop syndrome infectious bronchitis infectious bursal disease gallibacterium anatis vaccine infectious vaxxitekhvt ibd serotype live marek disease prevent mortality reduce bursal disease marek vector clinical sign lesion infectious disease bursal disease onset protection live vhvt recombinant week protection virus diluent extend week reduce mortality clinical sign lesion marek disease onset protection day single vaccination sufficient provide protection risk period vaccine salmonella gallimune bivalent vaccine active immunisation layer pullet enteritidis se oily adjuvant reduce salmonella enteritidis salmonella typhimurium st dissemination ovary reduce inactivated salmonella salmonella typhimurium salmonella enteritidis strain pt enteritidis dissemination inactivated salmonella intestinal tract typhimurium strain dt vaccine newcastle avinew live newcastle disease virus broiler chicken age disease nd vggaavinew strain day active immunisation newcastle disease reduce mortality clinical sign associate disease future layer future breeder pullet age week prime active immunisation egg drop cause newcastle disease vaccination inactivated vaccine strain ulster c prior beginning lie product portfolio animal health boehringer ingelheim livestock poultry continue companion animal horse main horse product focus prevention gastrogard ulcergard indicate treatment treatment parasite infestation management solution prevention equine gastric ulcer chronic disease vaccine equine portfolio common disease horse gastrogard include range flagship product treatment supply easytouse oral paste form joint disease colic respiratory disease pain management choice treatment gastric ulcer nutraceutical launch ulcergard usa preventive choice horse increase risk develop prascend indicate treatment pituitary gastric ulcer par intermedia dysfunction ppid know equine cushing disease clinical sign ppid eqvalanzimecterin contain ivermectin lead hypertrichiosis laminitis change body conformation ingredient control wide variety important lack performance treatment prascend internal parasite include bot benzimidazole lifelong resistant small strongyle easytoadminister oral paste eqvalanzimecterin approve adult vetera vaccine vaccine portfolio horse foal young week age include multiple convenient combination disease pro tection horse young month age eqvalan duogold zimecterin gold combine iver vaccine protect infectious mectin praziquantel ingredient specifically organism include influenza herpe west nile control tapeworm virus tetanus enable customised protec tion horse limited needle injection indication brand name active ingredient vaccine marek prevexxionrn live herpe virus chimera vaccine recommend ovo disease serotype vaccination dayold strain rn embryonate chicken egg protect virulent marek dis ease vaccine newcastle newxxitek hvt nd live marek disease vectore vaccination dayold marek disease virus serotype contain embryo onedayold chicken gene insert newcastle effective marek disease disease newcastle disease vaccine include diluent indication brand name active ingredient pituitary par intermedia prascend pergolide mesylate symptomatic treatment clinical sign dysfunction ppid associate pituitary par intermedia dysfunction ppid know equine cushing disease combination vaccine vetera eastern western venezuelan vaccination healthy horse common disease encephalomyelitis tetanus west aid prevention disease cause horse nile virus equine include antigen herpe virus equine canada influenza viruse treatment prevention gastrogard omeprazole treatment prevention recur equine gastric ulcer ulcergard rence gastric ulcer horse foal week age old treatment prevention eqvalan ivermectin treatment parasitic infestation internal parasite horse zimecterin horse donkey large eqvalan gold ivermectin small strongyle ascarid eqvalan duo praziquantel zimecterin gold goldduo include treatment tapeworm product portfolio animal health boehringer ingelheim companion animal pet pet portfolio offer diverse solution nexgard spectra combine flea tick efficacy important need canine feline health include afoxolaner nexgard broadspectrum industryleade parasiticide vaccine therapeutic deworme ingredient milbemycin oxime address major chronic disease heart failure kidney beefflavoure chew nexgard spectra disease epilepsy osteoarthritis effective treat flea tick protect dog deadly parasites heartworm lungworm year frontline leader gastrointestinal parasite flea tick control dog cat trust brand animal health frontline heartgard plus contain active ingredient continues bring innovation category ivermectin pyrantel soft beef chew give recent launch frontline triact feature monthly ivermectin effective prevent deadly repellency insecticidal efficacy disease heartworm disease pyrantel effective treatment carry fly insect decrease risk control round worm hookworm transmission vectorborne pathogen heartgard launch monthly heartworm preventative bestselle nexgard contain active ingredient afoxolaner heartworm preventative world oral medication treat flea tick dog efficacy palatable beefflavoure soft chew formulation nexgard currently well sell pet medication animal health industry datum file novel combination fipronil permethrin frontline triactfrontect reduce rick transmission babesia canis dermacentor reticulatus ehrlichia canis rhipicephalus sanguineus tick dog jongejan et al parasite vector datum file datum file indication brand name active ingredient antiparasitic caninefeline frontline fipronil frontline indicate treat external parasite frontline combo ment prevention flea tick frontline plus chew lice dog cat aid frontline triact frontect control sarcoptic mange dog antiparasitic canine external nexgard afoxolaner nexgard deliver highly parasite palatable beefflavoure chew kill adult flea indicate treatment prevention flea infesta tion treatment control tick infestation dog puppy month antiparasitic canine internal nexgard spectra afoxolaner nexgard spectra deliver external parasite milbemycin oxime highly palatable beefflavoure chew kill adult flea indicate treatment prevention flea tick infestation prevent heart worm disease treat control hookworm roundworm whipworm lungworm infestation dog puppy antiparasitic canine internal heartgard plus ivermectin use dog prevent canine heart parasite pyrantel worm disease eliminate tissue stage heartworm larvae month day infection treatment control roundworm hookworm product portfolio animal health boehringer ingelheim companion animal pet continue new class heart treatment term variety formulation offer veterinarian inodilator vetmedin show significantly owner flexibility use formulation prefer improve clinical sign extend life expectancy dog individual case manage level congestive heart failure originate dilate flammation pain associate license cardiomyopathy valvular insufficiency mitral andor indication tricuspid regurgitation recent study show preclinically appropriate asymptomatic pet vaccine product portfolio include purevax case dilate cardiomyopathy valvular feline vaccine formulate provide effective protection insuf ficiency vetmedin significantly delay onset use adjuvant clinical sign congestive heart failure metacam nonsteroidal antiinflammatory drug nsaid available oral suspension tablet injectable solution dog oral suspension injectable solution cat dog indication include alleviation inflammation pain acute chronic musculoskeletal disorder reduction pain follow surgery cat indica tion include alleviation inflammation pain acute chronic musculoskeletal disorder alleviation mild moderate postoperative pain indication brand name active ingredient congestive heart failure vetmedin pimobendan treatment canine congestive heart failure originate dilate cardio myo pathy valvular insufficiency mitral andor tricuspid regurgitation treatment dilate cardiomyopathy preclinical stage asymptomatic increase leave ventricular endsystolic enddiastolic diameter dober man pinscher treatment dog myxomatous mitral valve disease mmvd preclinical stage asymptomatic systolic mitral murmur evidence increase heart size delay onset clinical symptom heart failure p inflammatory metacam meloxicam dog metacam reduce disease postoperative pain inflammation follow orthopaedic eg fracture operation soft tissue surgery cat metacam reduce postoperative pain inflammation eg ovariohysterectomy spay operation orthopaedic minor soft tissue surgery alleviation pain inflammation acute chronic musculoskeletal disorder dog cat feline vaccine portfolio purevax feline herpes virus purevax fully adjuvantfree feline calicivirus feline vaccine range provide feline panleukopenia virus optimise safety profile adjuvant chlamydophila free protection component felv rabie powerful immune response adjuvant thank innovative canarypox technology felv rabie easy fit cat lifestyle allow ing compliance feline vaccina tion guideline sustain protection year rabie component comparison balance sheet financial datum boehringer ingelheim c h boehringer sohn ag co kg ingelheim comparison balance sheet financial datum million eur asset december intangible asset tangible asset financial asset fix asset inventory account receivable asset incl prepay expense defer taxis liquid fund current asset incl prepay expense defer taxis total asset liability equity december shareholder capital group reserve incl currency conversion difference equity attributable parent company noncontrolle interest group equity difference capital consolidation provision incl defer taxis account payable loan incl prepay expense liability incl defer taxis defer charge total liability equity summary select financial datum net sale operating income operating income net sale income taxis income taxis net sale return equity equity ratio financial fund personnel expense personnel expense net sale average number employee research development expense rd expense net sale investment tangible asset depreciation tangible asset p r n c h boehringer sohn ag co kg asset december binger strae intangible asset ingelheim germany tangible assets telephone financial asset fax fix asset contact inventory corporate division communication public affair account receivable asset email pressboehringeringelheimcom incl prepay expense defer taxis internet wwwboehringeringelheimcom liquid fund current asset incl prepay expense defer taxis issue c h boehringer sohn ag co kg total asset concept design layout liabilities equity december mpm corporate communication solution mainz wwwmpmde shareholders capital group reserve incl currency conversion difference photo equity attributable parent company andrea pohlmann noncontrolle interest print group equity neue sddeutsche verlagsdruckerei gmbh ulm difference capital consolidation provision incl defer taxis copyright c h boehringer sohn ag co kg account payable loan incl prepay expense right reserve annual report liability incl defer taxis defer charge reproduce transmit form mean total liability equity electronic photocopy permission write c h boehringer sohn ag co kg figure party annual report base datum available summary select financial datum time financial statement draw net sale operating income operating income net sale income taxis income taxis net sale return equity equity ratio financial fund personnel expense personnel expense net sale average number employee research development expense rd expense net sale investment tangible asset depreciation tangible asset wwwboehringeringelheimcom annualreportboehringeringelheimcom